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PlaintiffCi.t k K OF COURTS
APPLICATION FOR TRANSFER TO
BUSINESS AND CONSUMER DOCKET

V.

PFIZER, INC._______________
Defendant

I/W e submit this application for transfer of the above-captioned case to the BCD, based on the following information:

NAME OF EACH PARTY SUBMITTING THIS APPLICATION:

Plaintiff

STATE OF MAINE__________________'

Defendant

0

□

_______________________________________________

□

□

______________________ !_________

'□

□

_______________________________________________

□

□

1. Is at least one party a business entity?

[Zl Yes

□

No

2. List all plaintiffs and their counsel:
C O U N S E L (N A M E A N D A D D R E S S )

P L A IN T IF F (S )

STATE OF MAINE

E -M A IL A D D R E SS

CAROLYN A. SILSBY
carolyn.silsby@maine.gov
Bar No. 3030
Assistant Attorney General
6 State House Station
A u g u s ta ,
MF,__04333=0006----

3. List all defendants and their counsel:
C O U N S E L (N A M E A N D A D D R E S S )

D E F E N D A N T (S )

PFIZER, INC.

E -M A IL A D D R E S S

RUSSELL B. PIERCE, JR., ESQ rpierce@nhdlaw.com
Bar No. 7322
"i
Norman. Hanson & DeTrov. LL(
415 Congress Street
P D
B n y 4ftnn
P o r t l a n d ,
MF,
04112

4. List any other cases with which this case is or may need be consolidated or coordinated:
D O C K ET NUM BER

C A S E C A P T IO N

BCD-001

1

C U R R E N T C O U R T L O C A T IO N

5. What is the subject matter of the primary cause of action in this case:
□
□
□
□
□
□
□
□
□

Breach of Contract
Breach of Fiduciary Duty
80B Appeal involving a business entity
Internal governance of a business entity
Shareholder derivative action
Intellectual property
U.C.C. transactions
Antitrust or other trade regulations
Other (describe):

□
□
□
□
□
□
□

Breach of Warranty
Class Action
80C Appeal involving a business entity
Securities transactions
Confidential or trade secret
Financial transactions
Unfair trade practices
Commercial real estate

NOT YET
DETERMINED

6. What is the status of this case:
NO

YES

a. Has service of the complaint been completed on ail
parties?...........................................................................
b. Are the pleadings closed? ....... ....................................
c. Is discovery completed?................................................
d. Is class action status sought?........................................
e. Scheduled for trial? If so, w h en ?.................................
f. Pretrial h eld?..................................................................
g Case management conference held? ..........................
h. Jury trial? ....................................................................
i. Bench trial?........... .......... ................. i...... ;............ -....
j. ADR been attempted?.............. .....................................
k. Is file sealed (partial / entire)?.......................................
l. Will post-judgment judicial supervision be needed? ...

m. Consent Judgment Filed

□
□
□
□
□
□
□
□
□

□
□
□
□
□
□
□
□
□
□
□
□

□
□
□
□
□
□
□
□
□
□
□
□

X

□
□
□

7. What is the estimated length of trial (in days)? ___________
8.

Identify nature and num ber of any pending pretrial motions:

9.

Identify any novel and/or complex legal issues in this case:

10.

Do all of the parties appearing in the case agree to a transfer?

DO YES

CD NO

CERTIFICATION OF SERVICE BY ATTORNEY OR PARTY SUBMITTING APPLICATION

I hereby certify tbit à copy was mailcd/delivered to all obiinsel and pro se parties of record on this date
SIGNED:
- d / t w

yL A U A

u

/ •
VZÀ ir

DATE

/
ORuER (For BCD Court Use Only)

The above Application having been considered, it is ORDERED as follows:

B ^ T h e case is ACCEPTED for transfer. The case file shall be transferred forthwith from the court in which the case is now
pending to the BCD.
I~1 The case is NOT ACCEPTED for transfer.
SIGNED (BCD Justice/Judge)

________________

DATE /

]

\t/U

__________________________________
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/

PLEASE NOTE THE FOLLOWING:
A.
B.
C.
BCD-001

Failure to supply com plete and accurate information may disqualify a case for consideration for transfer to
the BCD.
Information that does not fit on this form should be attached to a separate sheet and numbered to correspond
to the inquiries on the form.
This application should be filed with the court in which the case is currently pending.
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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. C V -09-^ 3 <~J

STATE OF MAINE,
Plaintiff,
V.

PFIZER INC..
Defendant

)
)
)
)
)
)
)
)

CONSENT JUDGMENT

Plaintiff, the State of Maine, and Defendant, Pfizer Inc., voluntarily enter into this
Consent Judgment on the terms and conditions set forth below.
FINDINGS
A.

This Court has jurisdiction over the subject matter o f this lawsuit and over all

B.

The terms of this Consent Judgment shall be governed by the laws of the State of

C.

Entry o f this Consent Judgment is in the public interest and reflects a negotiated

Parties.

Maine.

agreement among the Parties.
D.

The Parties have agreed to resolve the issues related to the Covered Conduct

involving the prescription drug Geodon® by entering into this Consent Judgment.
E.

Pfizer is willing to enter into this Consent Judgment regarding the Covered

Conduct in order to resolve the Attorneys General’s concerns under the State Consumer

Protection Laws as to the matters addressed in this Consent Judgment and thereby avoid
unnecessary expense, inconvenience, and uncertainty.
F.

The Parties have agreed to resolve the issues raised by the Covered Conduct by

entering into this Consent Judgment,12
1.

Pfizer is entering into this Consent Judgment solely for the purpose of

settlement, and nothing contained herein may be taken as or construed to be an admission or
concession of any violation of law, rule, or regulation, or of any other matter of fact or law, or of
any liability or wrongdoing, all o f which Pfizer expressly denies. Pfizer does not admit any
violation o f the State Consumer Protection Laws set forth in footnote 1, and does not admit any
wrongdoing that was or could have been alleged by any Attorney General before the date of the
Consent Judgment under those laws. No part of this Consent Judgment, including its statements
and commitments, shall constitute evidence of any liability, fault, or wrongdoing by Pfizer. This
document and its contents are not intended for use by any third party for any purpose, including
submission to any court for any purpose.
2.

,

This Consent Judgment shall not be construed or used as a waiver or

limitation of any defense otherwise available to Pfizer in any action, or of Pfizer’s right to defend
itself from, or make any arguments in, any private individual, regulatory, governmental, or class
claims or suits relating to the subject matter or terms o f this Consent Judgment. This Consent
Judgment is made without trial or adjudication of any issue of fact or law or finding of liability
of any kind. Notwithstanding the foregoing, a State may file an action to enforce the terms of
this Consent Judgment.

1 This agreement is entered into pursuant to and subject to the State Consumer Protection laws cited in footnote 2.
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3.

It is the intent of the Parties that this Consent Judgment not be admissible

in other cases or binding on Pfizer in any respect other than in connection with the enforcement
of this Consent Judgment.
4.

No part of this Consent Judgment shall create a private cause of action or

confer any right to any third party for violation of any federal or state statute except that a State
may file an action to enforce the terms of this Consent Judgment.
G.

This Consent Judgment (or any portion thereof) shall in no way be construed to

prohibit Pfizer from making representations with respect to Geodon® that are required under
Federal law or required under any Investigational New Drug Application, New Drug
Application, Supplemental New Drug Application, or Abbreviated New Drug Application
approved by the FDA.
H.

Nothing in this Consent Judgment shall require Pfizer to:
(a) take any action that is prohibited by the FDCA or any regulation promulgated

thereunder, or by FDA; or
(b) fail to take any action that is required by the FDCA or any regulation
promulgated thereunder, or by the FDA.

Any written or promotional claim subject to this

Consent Judgment which is the same, or materially the same, as the language required or agreed
to by the Director of Division of Drug Marketing, Advertising and Communication or the
Director of the Center for Drug Evaluation and Research or their authorized designees in writing
shall not constitute a violation of this Consent Judgment, unless facts are or become known to
Pfizer that cause the claim to be false, misleading or deceptive.
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DEFINITIONS
The following definitions shall be used in construing this Consent Judgment:
1.

“Author” shall mean an HCP or health care institution engaged to produce articles

or other publications relating to Geodon®.
2.

“Clinically Relevant Information” shall mean information that reasonably prudent

clinicians would consider relevant when making prescribing decisions regarding Geodon®.
3.

“Consultant” shall mean an HCP engaged for services other than for speaker

programs (e.g., as a member of an advisory board or to attend consultant meetings) that relate to
Promotional and Product Related Functions.
4.

“Covered Conduct” shall mean Pfizer’s promotional and marketing practices,

sampling practices, dissemination of information and remuneration to HCPs regarding the
prescription drug Geodon® through the Effective Date of the Agreement.
5.

“Effective Date” shall mean the date on which a copy of this Consent Judgment,

duly executed by Pfizer and by the Signatory Attorney General, is approved by, and becomes a
Consent Judgment of, the Court, whichever is later.
6.

“Geodon®” shall mean all Pfizer Products that are FDA-approved drug

formulations containing ziprasidone or ziprasidone mesylate.
7.

“Health Care Professional” or “HCP” shall mean any physician or other health

care practitioner who is licensed to provide health care services or to prescribe pharmaceutical
products.
4

8.

“Labeling” shall mean all FDA-approved labels, which are a display of written,

printed, or graphic matter upon the immediate container of any article, and other written, printed,
or graphic matters (a) upon any article or any of its containers or wrappers, or (b) accompanying
such article.
9.

“Medical

Information

Letter” shall

mean

a non-Promotional,

scientific

communication to address Unsolicited Requests for medical information from HCPs.
10.

“Medical Outcomes Specialists” shall mean Pfizer personnel who have expertise

working with managed care to determine suitable drugs on a formulary and are assigned to the
Medical Outcomes Specialist group of Pfizer.
11.

“Medical Reference Publication” shall have the meaning ascribed to the term

“reference publication” found in 21 C.F.R. 99.3(i).

12.

“Medical Science Liaison” shall mean a person, usually with an advanced

scientific degree (e.g., a MD, PhD, or PharmD), assigned, employed, hired or retained by Pfizer
to provide scientific analysis and/or scientific information to HCPs and includes Regional
Medical Research Specialists.

13.

“Multistate Executive Committee” shall mean the Attorneys General and their

staffs representing Arizona, Colorado, Delaware, District of Columbia, Florida, Kentucky,
Maryland, Massachusetts, North Carolina, Ohio and Pennsylvania.
14.

“Multistate Working Group” shall mean the Attorneys General and their staff

representing Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, District
5

of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New
Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio,
Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont,
Washington, West Virginia, and Wisconsin.
15.

“Off-Label” shall mean a use not consistent with the indications section o f the

Geodon® Labeling approved by the FDA at the time information regarding such use was
communicated.
16.

“Parties” shall mean Pfizer and the Signatory Attorney General.

17.

“Payment” is defined to include all payments or transfers of value (whether in

cash or in kind) made to physicians including all payments (including, for example, honoraria
payments, other payments, and reimbursement for lodging, travel and other expenses) made in
connection with physicians serving as speakers, participating in speaker training, or serving as
Consultants or Authors; payments or compensation for services rendered; grants; fees; payments
relating to research; payments relating to education; and payment or reimbursement for food,
entertainment, gifts, trips or travel, product(s)/item(s) provided for less than fair market value, or
other economic benefit paid or transferred. The term also includes all payments or transfers of
value made to Related Entities on behalf of, at the request of, for the benefit or use of, or under
the name of a physician for whom Pfizer would otherwise report a Payment if made directly to
the physician. The term “Payments” includes any Payments made, directly or indirectly, by
Pfizer to a physician or Related Entity in connection with, or under the auspices of, a co
promotion arrangement. The term “Payments” does not include: i) samples of drug products that
6

meet the definition set forth in 21 C.F.R. § 203.3(i), or ii) discounts, rebates, or other pricing
terms. Only for purposes of the reporting of Payments on March 31, 2011, the term “Payments”
does not include: i) individual Payments of less than $25 per instance, or ii) aggregate Payments
in a year to a physician or Related Entity o f less than $500. Beginning with the March 31, 2012
report and all reports thereafter, individual Payments under $25 per instance and aggregate
Payments of less than $500 shall be included in the Payment amounts listed in the applicable
report.
18.

“Pfizer Inc.” or “Pfizer” shall mean Pfizer Inc., including all of its affiliates,

subsidiaries and divisions, predecessors, successors and assigns doing business in the United
States.
19.

“Pfizer Medical Education Grants Office” shall mean the U.S.-based organization

within Pfizer responsible for oversight of the continuing medical education (CME) grant process,
including the acceptance, review, and approval of all non-clinical CME grant requests.
20.

“Pfizer Marketing” shall mean Pfizer personnel assigned to the Pfizer U.S.

Geodon® marketing team(s).
21.

“Pfizer Medical” shall mean Pfizer personnel assigned to the Pfizer medical

organization.
22.

“Pfizer Sales” shall mean the Pfizer sales force responsible for U.S. Geodon®

sales, including but not limited to Medical Outcomes Specialists.
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23.

“Promotional,” “Promoting” or “Promote” shall mean claims about Geodon®

intended to increase sales or attempt to influence prescribing practices of HCPs, including directto-consumer as applicable.
24.

“Promotional and Product Related Functions” includes: (a) the selling, detailing,

marketing, advertising, promoting, or branding of Geodon®; (b) the development, preparation,
or dissemination of materials or information about, or the provision of services relating to,
Geodon® including those functions relating to material review committees and Pfizer’s Medical
Information Department; and (c) research, development, and publication related-activities
involving Geodon®, including postmarketing and other studies, and the authorship, publication
and disclosure of study results.

25.

“Promotional Materials” shall mean any item with the product name, logo, or

message used to Promote Geodon®.
26.

“Promotional Slide Kit” shall mean Promotional Materials regarding Geodon® in

the form of a slide kit for use in speaker programs.
27.

“Promotional Speaker” shall mean a non-Pfizer employee HCP speaker used to

Promote Geodon®.
28.

“Related Entity” is any entity by or in which any physician receiving Payments is

employed, has tenure, or has an ownership interest.

29.

“Reprints Containing Off-Label Information” shall mean articles or reprints from

a peer reviewed journal or reference publication describing an Off-Label use of Geodon®.
8

30.

“Signatory Attorney General” shall mean the Attorney General of Maine, or her

authorized designee, who has agreed to this Consent Judgment.
31.

“State Consumer Protection Laws” shall mean the consumer protection laws

under which the Attorneys General have conducted the investigation.2
32.

“Unsolicited Request” shall mean a request for information regarding Geodon®

from a non-Pfizer HCP communicated to an agent of Pfizer that has not been prompted.
COMPLIANCE PROVISIONS

I.

Promotional Activities
A.

Pfizer shall not make any written or oral claim that is false, misleading or

deceptive regarding Geodon®.

2 ALABAMA - Alabama Deceptive Trade Practices Act, Ala. Code § 8-19-1 et seq.; ARIZONA - Arizona Consumer Fraud Act, A.R.S. § 441521 et seq:, ARKANSAS - Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101, etseq.; CALIFORNIA - Bus. & Prof Code §§
17200 et seq and 17500 et seq.; COLORADO - Colorado Consumer Protection Act, Colo. Rev. Stat. § 6-1-101 et seq.; DELAWARE Delaware Consumer Fraud Act, Del CODE ANN. tit. 6, §§ 2511 to 2527; DISTRICT OF COLUMBIA, District o f Columbia Consumer
Protection Procedures Act, D.C. Code §§ 28-3901 etseq.; FLORIDA - Florida Deceptive and Unfair Trade Practices Act, Part II, Chapter 501,
Florida Statutes, 501.201 et. seq.; HAWAII - Uniform Deceptive Trade Practice Act, Haw. Rev. Stat. Chpt. 481A and Haw. 501.201 et seq.;
IDAHO - Consumer Protection Act, Idaho Code Section 48-601 et seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices Act,
815 ILCS 505/2 et seq.; IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16; KANSAS - Kansas Consumer Protection Act, K.S.A.
50-623 et seq. KENTUCKY —Kentucky Consumer Protection Act, KRS Ch. 367.110, et seq.; LOUISIANA - Unfair Trade-Practices and
Consumer Protection Law, LSA-R.S. 51:1401, et seq.; MAINE — Unfair Trade Practices Act, 5 M.R.S.A. § 207 et seq.; MARYLAND Maryland Consumer Protection Act, Md Code Ann., Com. Law §§ 13-101 et seq.; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4;
MICHIGAN - Michigan Consumer Protection Act, MCL § 445.901 et seq.; MINNESOTA - Minnesota Deceptive Trade Practices Act, Minn.
Stat. §jj 325D.43-48; Minnesota False Advertising Act, Minn. Stat. § 325F.67; Minnesota Consumer Fraud Act, Minn. Stat. §§ 325F.68-70;
Minnesota Deceptive Trade Practices Against Senior Citizens or Disabled Persons Act, Minn. Stat. § 325F.71.; MISSOURI - Missouri
Merchandising Practices Act, Mo. Rev. Stat. §§ 407 etseq.; MONTANA - Montana Code Annotated 30-14-101 etseq: NEBRASKA - Uniform
Deceptive Trade Practices Act, NRS §§ 87-301 et seq.; NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.;
NEW JERSEY - New Jersey Consumer Fraud Act, NJSA 56:8-1 et seq. ; NEW MEXICO - NMSA 1978, § 57-12-1 et seq.; NEW YORK General Business Law Art. 22-A, tj§ 349-50, and Executive Law § 63(12); NORTH CAROLINA - North Carolina Unfair and Deceptive Trade
Practices Act, N.C.G.S. 75-1.1, et seq.; NORTH DAKOTA - Unlawful Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.;
OHIO - Ohio Consumer Sales Practices Act, R.C. 1345.01, et seq.; OREGON - Oregon Unlawful Trade Practices Act, Or. Rev. Stat. § 646.605
et seq.; PENNSYLVANIA - Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 P.S. 201-1 et seq.; SOUTH CAROLINASouth Carolina Unfair Trade Practices Act, sections 39-5-10 et seq.; SOUTH DAKOTA - South Dakota Deceptive Trade Practices and
Consumer Protection, SDCL ch. 37-24; TENNESSEE —Tennessee Consumer Protection Act, Tenn. Code Ann. 47-18-101 et seq,; TEXAS Texas Deceptive Trade Practices-Consumer Protection Act, Tex. Bus. And Com. Code 17.47, et seq.; VERMONT —Consumer Fraud Act, 9
V.S.A. §§ 2451 et seq.; WASHINGTON —Unfair Business Practices/Consumer Protection Act, RCW §§ 19.86 et seq.; WEST VIRGINIA West Virginia Consumer Credit and Protection Act, W. Va. Code § 46A-1101 et seq.; WISCONSIN — Wis Stat. § 10018 (Fraudulent
Representations).
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B.

In Promotional Materials for Geodon®, Pfizer shall clearly and conspicuously

disclose the most serious risks associated with the product as set forth in the product’s labeling,
including information in any black box warning and shall present information about
effectiveness and information about risk in a balanced manner.
C.

Pfizer shall not Promote Geodon® for Off-Label uses.

D.

Pfizer shall not present patient profiles/types based on selected symptoms of the

FDA-approved indication(s) when Promoting Geodon®, unless:
1.

Geodon®’s specific FDA-approved indication(s) being Promoted is/are

stated clearly and conspicuously on the same page or on a facing page in any physical Promotional
Materials that reference the selected symptoms;
a.

With respect to Promotional Slide Kits or computer tablet based
Promotional Materials:
(i)

Pfizer shall state clearly and conspicuously the FDAapproved indication(s) on the same slide in which selected
symptoms are first presented;

(ii)

Pfizer shall include a short-hand reference to the statement
described in Section I.D.l.a.(i) on the same slide as each
subsequent reference to selected symptoms (e.g., “See
complete list of FDA-approved indications at p. X”); and
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b.

With respect to Promotional Slide Kits, Pfizer shall require any
presenter of Pfizer’s Promotional Slide Kits to present the
statements required in Section I.D.l.a.(i), as part of the mandatory
slides.

2.

Promotional

Materials have a reference indicating that the full

constellation of symptoms and the relevant diagnostic criteria are available in the Diagnostic and
Statistical Manual o f Mental Disorders (DSM-IV or current version), where applicable.
E.

Pfizer shall ensure that all Promotional Speakers’ Promotional Materials for

Geodon® comply with Pfizer’s obligations in the above Sections I.A. - D.
F.

Pfizer shall not award prizes or other incentives to its sales force as rewards for

the Off-Label sales or use of Geodon®.
II.

Dissemination and Exchange of Medical Information
A.

The content of Pfizer’s communications concerning Off-Label uses of Geodon®

shall not be false, misleading or deceptive.
B.

Medical Information Letters
1.

The following subsections shall be effective for nine years from the

Effective Date of this Consent Judgment.
2.

Pfizer Medical shall have ultimate responsibility for developing and

approving the medical content for all Medical Information Letters regarding Geodon®, including

11

any that may describe Off-Label information. Additional approvals may be provided by Pfizer’s
legal department. Pfizer shall not distribute any such materials unless:
a.

Clinically Relevant Information is included in these materials to
provide scientific balance;

b.

Data in these materials are presented in an unbiased, nonPromotional manner; and

c.

These materials are clearly distinguishable from sales aids and
other Promotional Materials.

3.

Pfizer Sales and Pfizer Marketing personnel shall not develop the medical

content of Medical Information Letters regarding Geodon®. This provision does not prohibit
Pfizer Sales or Pfizer Marketing personnel from suggesting topics for Medical Information
Letters.
4.

Pfizer Sales and Pfizer Marketing personnel shall not distribute Medical

Reference Publications or Medical Information Letters regarding Geodon®.

5.

Pfizer shall not knowingly disseminate any Medical Information Letter

describing any Off-Label use of Geodon® that makes any false, misleading or deceptive
representation regarding Geodon® or any false, misleading or deceptive statement concerning a
competing product.
C.

Responses to Unsolicited Requests for Off-Label Information

12

1.

The following subsections shall be effective for nine years from the

Effective Date of this Consent Judgment.
2.

In responding to an Unsolicited Request for Off-Label information

regarding Geodon®, including any request for a specific article related to Off-Label uses, Pfizer
shall advise the requestor that the request concerns an Off-Label use and inform the requestor of
the drug’s FDA-approved indication(s) and/or dosage and other relevant Labeling information.
3.

If Pfizer elects to respond to an Unsolicited Request for Off-Label

information from a HCP regarding Geodon®, Pfizer Medical personnel shall provide specific,
accurate, objective, and scientifically balanced responses. Any such response shall not Promote
Geodon® for any Off-Label use(s).
4.

Any written response to an Unsolicited Request for Off-Label information

regarding Geodon® shall include:
a.

an existing Medical Information Letter prepared in accordance
with Section II.B;

b.

a Medical Information Letter or other document prepared in
response to the request in accordance with Section II.B; or

c.

a report containing the results of a reasonable literature search
using terms from the request.

5.

Pfizer Sales and Pfizer Marketing personnel may respond in writing to an

Unsolicited Request for Off-Label information regarding Geodon® from an HCP only by
13

informing the HCP o f the presence or absence of published studies concerning the Off-Label
topic or by acknowledging whether the topic is an area of research, and by offering to request on
behalf of the HCP that a Medical Information Letter or other information be sent to the HCP in
follow up, provided it complies with sub-Section II.C.4 set forth above. Pfizer Sales and Pfizer
Marketing personnel shall not characterize, describe, identify, name, or offer any opinions about
or summarize any such Off-Label information.

Notwithstanding the foregoing, Medical

Outcomes Specialists may discuss in writing issues relating to pharmacoeconomics or health
outcomes with third party payors, including but not limited to managed care organizations and
employers responsible for the administration of health benefits, but not prescribers unless
employed or engaged by payors in a non-prescribing role.
6.

Pfizer Sales and Pfizer Marketing personnel may respond orally to an

Unsolicited Request for Off-Label information regarding Geodon® from an HCP only by
informing the HCP o f the presence or absence o f published studies concerning the Off-Label
topic or by acknowledging whether the topic is an area of research, and by offering to request on
behalf of the HCP that a Medical Information Letter or other information be sent to the HCP in
follow up, provided it complies with sub-Section II.C.4 set forth above. Pfizer Sales and Pfizer
Marketing personnel shall not characterize, describe, identify, name, or offer any opinions about
or summarize any such Off-Label information.

Notwithstanding the foregoing, Medical

Outcomes Specialists may discuss orally issues relating to pharmacoeconomics or health
outcomes with third party payors, including but not limited to managed care organizations and
employers responsible for the administration of health benefits, but not prescribers unless
employed or engaged by payors in a non-prescribing role.
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D.

Reprints
1.

Pfizer shall not disseminate any information describing any Off-Label use

of Geodon® if such use has been submitted to the FDA for approval and the FDA has either
advised Pfizer that it refuses to approve such application or that FDA-identified deficiencies
must be resolved before approval can be granted unless Pfizer has first clearly and conspicuously
disclosed to the recipient of the information that the FDA had issued such advice regarding such
Off-Label use. Pfizer may disclose to any recipient of such information whether the information
was presented to the FDA prior to the FDA’s issuance of such advice regarding the Off-Label
use.
2.

Pfizer shall not disseminate a Medical Information Letter, an unabridged

reprint or copy of an article from a peer reviewed journal or a Reference Publication, or
written information through a Regional Medical Research Specialist (“RMRS”)
describing any Off-Label use of Geodon® in response to an Unsolicited Request unless:
a.

the information is about a clinical investigation with respect to
Geodon® and experts qualified by scientific training or experience
to evaluate the safety or effectiveness of Geodon® would consider
the subject of the clinical investigation to be scientifically sound or
the information is an unabridged reprint or copy of an article from
a peer reviewed journal or a Reference Publication;
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b.

the information is accompanied by a comprehensive bibliography
of publications discussing adequate and well-controlled clinical
studies published in a medical journal or medical or scientific text
that have been previously published about the use of Geodon®
covered by the information (unless the information is a peer
reviewed journal or Reference Publication which already includes
such a bibliography); and

c.

in cases in which experts qualified by scientific training or
experience to evaluate the safety or effectiveness of Geodon®
would consider the conclusion of the information to have been
specifically called into question by another article(s) or text(s) that
experts qualified by scientific training or experience to evaluate the
safety or effectiveness o f Geodon® would consider to be
scientifically sound, the information must be disseminated with a
representative publication that reaches contrary or different
conclusions regarding the Off-Label use.

3.

Reprints Containing Off-Label Information
a.

Pfizer Medical shall be responsible for the identification, selection,
approval and dissemination of Reprints Containing Off-Label
Information regarding Geodon®.

b.

Reprints Containing Off-Label Information regarding Geodon®:
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(i) shall be accompanied by the full prescribing information
for the product and contain a disclosure in a prominent
location, which would include the first page or as a cover
page where practicable, indicating that the article may
discuss Off-Label information; and
(ii) shall not be referred to or used in a Promotional manner.
c.

Reprints Containing Off-Label Information regarding Geodon®
may only be disseminated by Pfizer Medical personnel to HCPs.
Pfizer Sales or Pfizer Marketing personnel shall not disseminate
these materials to HCPs, absent the exception described below in
(i); provided, however, that Medical Outcomes Specialists may
disseminate reprints relating to pharmacoeconomics or health
outcomes to third party payors, including but not limited to
managed care organizations and employers responsible for the
administration of health benefits, but not prescribers unless
employed or engaged by payors in a non-prescribing role.
(i) In the event of an extraordinary circumstance in which
there is a clinical necessity to have Pfizer Sales or Pfizer
Marketing personnel disseminate a Reprint Containing OffLabel information directly to HCPs, the President o f Pfizer
Worldwide Pharmaceutical Operations may approve a
Clinical Necessity Exception to the prohibition described in
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Section II.D.3.C above for that Reprint Containing OffLabel information.
(ii) If the Clinical Necessity Exception is invoked, Pfizer will
notify each Signatory Attorney General of its intent to
invoke the Clinical Necessity Exception at least 30 business
days

prior

to

representatives

disseminating
any

Reprint

through

Pfizer

Containing

sales

Off-Label

information on Geodon®.
(a) If a Signatory Attorney General believes the Reprint
Containing Off-Label information to be disseminated
does not meet the Clinical Necessity Exception, then
the State will provide Pfizer with written notice within
30 business days and provide Pfizer an opportunity to
discuss its desired use of the Reprint Containing OffLabel information pursuant to the limited exception.
(b) If the State and Pfizer do not come to a resolution, then
the State may initiate legal action to prevent the
dissemination of the Reprint Containing Off-Label
information by Pfizer Sales or Pfizer Marketing
personnel.
(c) If the State initiates legal action to prevent the
dissemination of the Reprint Containing Off-Label
information by Pfizer Sales or Pfizer Marketing
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personnel, Pfizer shall not use Pfizer Sales or Pfizer
Marketing personnel to disseminate such Reprint
Containing Off-Label information in that State until the
issue has been resolved.
4.

Nothing

in

this

Consent

Judgment

shall

preclude

Pfizer

from

disseminating Reprints Containing Off-Label information which have an incidental reference to
Off-Label information. If reprints have an incidental reference to Off-Label information, such
reprints shall contain the disclosure required by Section II.D.3.b(i) in a prominent location, as
defined above.
5.

Pfizer shall not disseminate any reprint or copy of an article from a peer

reviewed journal or a Medical Reference Publication describing any Off-Label use of Geodon®
to physician specialties that do not customarily prescribe Geodon® if these materials combined
with detailing, advertising, sampling, or other Promotional activities Promote Off-Label use of
Geodon®.
6.

In disseminating information about Off-label usage, Pfizer shall either

follow the substantive procedures in Section IV o f the January, 2009, FDA guidance entitled
Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific
Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared
Medical Devices or use an alternative approach provided such approach satisfies the
requirements of the applicable statutes and regulations.
E.

Pfizer shall develop, implement and maintain policies and procedures to ensure

that Medical Science Liaisons do not promote Off-label uses of Geodon® and to ensure that they
do not engage in the improper marketing o f Geodon®.
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III.

Continuing Medical Education (CME) and Grants

A.

The following subsections shall be effective for six years from the Effective Date

of this Consent Judgment.
B.

Pfizer shall disclose information about grants, including CME grants, regarding

Geodon® consistent with the current disclosures of the Pfizer Medical Education Grants Office
registry at http://www.pfizer.com/responsibilitv/erants pavments/medical education grants.isp
(hereinafter, “Pfizer Medical Education Grants Office website”) or as required by applicable law.
1.

Once posted, Pfizer shall maintain this information on the Pfizer Medical

Education Grants Office website for at least two years and shall maintain the information in a
readily accessible format for review by the States upon written request for a period of five years.
C.

The Pfizer Medical Education Grants Office shall manage all requests for funding

related to CME relating to Geodon®. Approval decisions shall be made by the Pfizer Medical
Education Grants Office and Pfizer Medical, and shall be kept separate from the Pfizer Sales and
Pfizer Marketing organizations.
D.

Pfizer shall not use grants to Promote Geodon®. This provision includes, but is

not limited to, the following prohibitions:
1.

Pfizer Sales and Pfizer Marketing personnel shall not initiate, coordinate

or implement grant applications on behalf of any customer or HCP;
2.

Pfizer Sales and Pfizer Marketing personnel shall not be involved in

selecting grantees or CME-funded speakers; and
3.

Pfizer Sales and Pfizer Marketing personnel shall not measure or attempt

to track in any way the impact of grants or speaking fees on the participating HCPs’ subsequent
prescribing habits, practices or patterns.
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E.

Pfizer shall not condition funding of a CME program grant request relating to

Geodon® upon the requestor’s selection or rejection of particular speakers.
F.

Pfizer shall not suggest, control, or attempt to influence selection of the specific

topic, title, content, speakers or audience for CMEs relating to Geodon®, consistent with
ACCME guidelines.
G.

Pfizer Sales and Pfizer Marketing personnel shall not approve grant requests

regarding Geodon®, nor attempt to influence the Pfizer Medical Education Grants Office to
reward any customers or HCPs with grants for their prescribing habits, practices or patterns.
H.

Pfizer shall contractually require the CME provider to disclose to CME program

attendees Pfizer’s financial support of the CME program and any financial relationship with
faculty and speakers at such CME.
I.

After the initial delivery of a CME program, Pfizer shall not fund the same

program, nor shall it provide additional funding for re-distribution of the same program, if Pfizer
Medical Education Grants Office or Pfizer Medical knows that the program’s speakers are
Promoting Geodon® for Off-Label uses, unless it takes specific action that ensures that such
Promotion does not occur.
IV.

Payments to Speakers and HCPs
A.

On or before March 31, 2011, Pfizer shall post in a prominent position on its

website an easily accessible and readily searchable listing of all U.S.-based physicians, and
Related Entities who or which received Payments directly or indirectly from Pfizer between July
I, 2010 and December 31, 2010 and the aggregate value of such Payments.
B.

After the initial posting, Pfizer shall post annual listings on March 31, 2012 and

March 31 o f each o f the three successive years. The annual listing on March 31, 2012 and
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thereafter shall include cumulative information about Payments made by Pfizer during each of
the respective prior calendar years.
C.

In addition, beginning on June 1, 2012, Pfizer shall include on its website a listing

of all U.S. based physicians and Related Entities who or which received Payments from Pfizer
during the first calendar quarter of 2012. Thereafter, 60 days after the end o f each subsequent
calendar quarter, Pfizer shall also post on its website a listing of updated information about all
Payments provided during the preceding quarter(s) in each calendar year. The quarterly and
annual reports shall be easily accessible and readily searchable.
D.

Each listing made pursuant to this section shall include a complete list of all

individual physicians, and/or Related Entities to whom or to which Pfizer directly or indirectly
made Payments in the preceding calendar year for 2011 and after June 1, 2012 for the preceding
quarter or year (as applicable). Each listing shall be arranged alphabetically according to the
physicians’ last name or the name o f the Related Entity. The Payment amounts in the lists shall
be reported in $10,000 increments (e.g., $0 - $10,000; $10,001- $20,000; etc.) or in the actual
amount paid, provided, however, that the Payment amounts shall be listed in the same way
(incrementally or in actual amounts) for all physicians and/or Related Entities on the listing. For
each physician, the applicable listing shall include the following information: i) physician’s full
name; ii) name of any Related Entities (if applicable); iii) city and state that the physician or
Related Entity has provided to Pfizer for contact purposes; and (iv) the aggregate value of the
Payment(s) in the preceding quarter(s) or year (as applicable).

If Payments for multiple

physicians have been made to one Related Entity, the aggregate value of all Payments to the
Related Entity will be the reported amount.
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E.

Pfizer shall continue to make each annual listing and the most recent quarterly

listing of Payments available on its website at least through March 31, 2014. Pfizer shall retain
and make available to the State, upon request, all work papers, supporting documentation,
correspondence, and records related to all applicable Payments and to the annual and quarterly
listings of Payments. Nothing in this section affects the responsibility of Pfizer to comply with
(or liability for noncompliance with) all applicable Federal health care program requirements and
state laws as they relate to all applicable Payments made to physicians or Related Entities.
F.

If the proposed Physician Payments Sunshine Act of 2009 or similar legislation is

enacted, the State shall determine whether the purposes of this section are reasonably satisfied by
Pfizer’s compliance with such legislation. In such case, and in its sole discretion, the State may
agree to modify or terminate provisions o f this section as appropriate.
G.

The term “physician” as used in this section does not include bona-fide employees

of Pfizer or its subsidiaries.
H.

Pfizer’s posting o f Payment information shall be subject to any applicable

confidentiality provisions contained in clinical research agreements that were entered with a
U. S.-based physician prior to July 1, 2009. Pfizer agrees that it shall not include any such
confidentiality provisions in any new or renewed clinical research agreements entered after the
Effective Date o f this Consent Judgment that require any Payment to a U.S.-based physician.
V.

Product Samples
A.

The following subsections shall be effective for nine years from the Effective

Date of this Consent Judgment.
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B.

Pfizer shall only provide samples of Geodon® to those HCPs who have

specialties that customarily treat patients who have diseases for which treatment with Geodon®
would be consistent with Geodon®’s Labeling.
C.

If a HCP whose clinical practice is inconsistent with the product’s Labeling

requests samples, Pfizer personnel shall refer the practitioner to 1-800-438-1985 where the
practitioner can speak directly with a Pfizer representative who will provide answers to the
HCP’s questions about Geodon® and may provide them with samples only if appropriate (i.e., if
the physician requests the sample for an on-label use).
D.

Pfizer shall not disseminate samples of Geodon® with the intent of increasing

Off-Label prescribing of Geodon®.
VI.

Clinical Research
A.

Pfizer shall report research regarding Geodon® in an accurate, objective and

balanced manner as follows and as required by applicable law:
1.

To the extent permitted by the National Library of Medicine and as

required by the FDA Amendments Act (Public Law No. 110-85), Pfizer shall register clinical
trials and submit results to the registry and results data bank regarding Geodon® as required by
the FDA Amendments Act and any accompanying regulations that may be promulgated pursuant
to that Act. With respect to Geodon®, Pfizer shall register on a publicly accessible website all
Pfizer-sponsored Phase II, III and IV clinical trials, to the extent available, that were ongoing or
initiated after July 1, 2005 and will post results on a publicly accessible website of all Pfizersponsored Phase II, III and IV clinical trials, to the extent available, that were completed after
October 2002.

24

B.

When presenting information about a clinical study regarding Geodon® in any

Promotional Materials, Pfizer shall not do any o f the following:
1.

present favorable information or conclusions from a study that is

inadequate in design, scope, or conduct to furnish significant support for such information or
conclusions;
2.

use the concept of statistical significance to support a claim that has not

been demonstrated to have clinical significance or validity, or fails to reveal the range of
variations around the quoted average results;
3.

use statistical analyses and techniques on a retrospective basis to discover

and cite findings not soundly supported by the study, or to suggest scientific validity and rigor
for data from studies the design or protocol of which are not amenable to formal statistical
evaluations;
4.

present the information in a way that implies that the study represents

larger or more general experience with the drug than it actually does; or
5.

use statistics on numbers of patients, or counts of favorable results or side

effects, derived from pooling data from various insignificant or dissimilar studies in a way that
suggests either that such statistics are valid if they are not or that they are derived from large or
significant studies supporting favorable conclusions when such is not the case.
VII.

Terms Relating to Payment
A.

No later than 30 days after the Effective Date of this Order, Pfizer shall pay a total

amount of $33 million to be divided and paid by Pfizer directly to each Signatory Attorney
General o f the Multistate Working Group in an amount to be designated by and in the sole
discretion o f the Multistate Executive Committee. Said payment shall be used by the States as
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and for attorneys’ fees and other costs of investigation and litigation, or to be placed in, or
applied to, the consumer protection enforcement fund, including future consumer protection
enforcement, consumer education, litigation or local consumer aid fund or revolving fund, used
to defray the costs of the inquiry leading hereto, and may be used to fund or assist in funding
programs directed at mental illness treatment, including but not limited to education and outreach
or for other uses permitted by state law, at the sole discretion o f each Signatory Attorney
General. The Parties acknowledge that the payment described herein is not a fine penalty, or
payment in lieu thereof.
VIII.

Release
A.

By its execution of this Consent Judgment, the State o f Maine releases Pfizer and

all of its past and present subsidiaries, affiliates, predecessors and successors (collectively, the
“Released Parties”) from the following: all civil claims, causes o f action, damages, restitution,
fines, costs, and penalties that the Maine Attorney General could have asserted against the
Released Parties under the above-cited consumer protection statutes resulting from the Covered
Conduct up to and including the Effective Date that is the subject of this Consent Judgment.
B.

Notwithstanding any term of this Consent Judgment, specifically reserved and

excluded from the Release in Paragraph VIII.A. as to any entity or person, including Released
Parties, are any and all of the following:
1.

Any criminal liability that any person and/or entity, including Released

Parties, has or may have to the State of Maine.
2.

Any civil or administrative liability that any person and/or entity,

including Released Parties, has or may have to the State of Maine not expressly covered by the
release in Paragraph (A) above, including but not limited to any and all of the following claims:
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a)

State or federal antitrust violations;

b)

Reporting practices, including “best price”, “average wholesale
price” or “wholesale acquisition cost;”

c)

Medicaid violations, including federal Medicaid drug rebate statute
violations, Medicaid fraud or abuse, and/or kickback violations
related to any State’s Medicaid program; and,

d)
3.

State false claims violations.

Any liability under the State of Maine’s above-cited consumer protection

laws which any person and/or entity, including Released Parties, has or may have to individual
consumers or State program payors of said State.
4.

Any liability for failure to comply with Maine’s Prescription Drug Clinical

Trial Reporting Rule: DHS Rule 10-144 Ch. 275, AG Rule 26-0259 Ch. 11 with respect to any
drug other than Geodon.
IX

Nothing contained in this Judgment Order shall relieve or release Pfizer of the obligations

it maintains under any other Consent Judgment or agreement relating to any Pfizer product.
X.

Dispute Resolution
A.

For the purposes of resolving disputes with respect to compliance with this

Consent Judgment, should any of the Signatory Attorneys General have a reasonable basis to
believe that Pfizer has engaged in a practice that violates a provision o f this Consent Judgment
subsequent to the Effective Date of this Judgment, then such Attorney General shall notify Pfizer
in writing of the specific objection, identify with particularity the provisions of this Consent
Judgment that the practice appears to violate, and give Pfizer thirty (30) days to respond to the
notification; provided, however, that a Signatory Attorney General may take any action if the
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Signatory Attorney General concludes that, because of the specific practice, a threat to the health
or safety of the public requires immediate action. Upon receipt of written notice, Pfizer shall
provide a good-faith written response to the Attorney General notification, containing either a
statement explaining why Pfizer believes it is in compliance with the Consent Judgment, or a
detailed explanation of how the alleged violation occurred and a statement explaining how Pfizer
intends to remedy the alleged breach. Nothing in this paragraph shall be interpreted to limit the
state’s Civil Investigative Demand (“CID”) or investigative subpoena authority, to the extent
such authority exists under applicable state law, and Pfizer reserves all of its rights with respect
to a CID or investigative subpoena issued pursuant to such authority.
B.

Upon giving Pfizer thirty (30) days to respond to the notification described above,

the Signatory Attorney General shall also be permitted reasonable access to inspect and copy
relevant, non-privileged, non-work product records and documents in the possession, custody or
control of Pfizer that relate to Pfizer’s compliance with each provision of this Consent Judgment
as to which cause that is legally sufficient in the State has been shown. If the Signatory Attorney
General makes or requests copies of any documents during the course of that inspection, the
Signatory Attorney General will provide a list of those documents to Pfizer.
C.

The State may assert any claim that Pfizer has violated this Consent Judgment in a

separate civil action to enforce compliance with this Consent Judgment, or may seek any other
relief afforded by law, but only after providing Pfizer an opportunity to respond to the
notification described in Paragraph X.A. above; provided, however, that a Signatory Attorney
General may take any action if the Signatory Attorney General concludes that, because of the
specific practice, a threat to the health or safety of the public requires immediate action.
XI.

General Provisions
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A.

This Consent Judgment represents the full and complete terms of the settlement

entered into by the Parties hereto. In any action undertaken by the Parties, no prior versions of
this Consent Judgment and no prior versions of any of its terms that were not entered by the
Court in this Consent Judgment, may be introduced for any purpose whatsoever.
B.

This Court retains jurisdiction of this Consent Judgment and the Parties hereto for

the purpose of enforcing and modifying this Consent Judgment and for the purpose of granting
such additional relief as may be necessary and appropriate.
C.

This Consent Judgment may be executed in counterparts, and a facsimile or PDF

signature shall be deemed to be, and shall have the same force and effect as, an original
signature.
D.

All Notices under this Order shall be provided to the following via Overnight

Mail:
For the State of Maine:

Chief, Consumer Protection Division
Office o f the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006

For Pfizer Inc.:

Douglas M. Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
150 East 42nd Street
New York, New York 10017

E.

To the extent that any provision of this Consent Judgment obligates Pfizer to

change any policy(ies) or procedure(s) and to the extent not already accomplished, Pfizer shall
implement the policy(ies) or procedure(s) as soon as reasonably practicable, but no later than 120
days after the Effective Date o f this Consent Judgment.
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IT IS HEREBY ORDERED, ADJUDGED AND DECREED.

For Plaintiff:

JANET T. MILLS
ATTORNEY GENERAL

Dated: September»^, 2009
ASSISTANT ATTORNEY GENERAL
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207)626-8829
Carolyn.silsby@maine.gov
ATTORNEYS FOR THE STATE OF MAINE
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For Defendant:

Dated: September 2. , 2009
RUSSELL B. PIERCE, JR., Bar No.
Norman, Hanson & DeTroy, LLC
415 Congress Street
P.O. Box 4600
Portland, ME 04112-4600
(207) 774 7000
ATTORNEY FOR PFIZER INC.
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For Pfizer Inc,:

Douglas M, Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
Date:_____

By:
Robert P.Sfierman
DLA Piper LLP (US)
33 Arch Street, 26th Floor
Boston, MA 02110

Brien T. O’Connor
Ropes & Gray
One International Place
Boston, MA 02 NO
Date::

«Lì1
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Date :
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*

F o r P fiz e r In c .:

Douglas M. Lankier
Senior Vice President
And Chief Compliance Officer
Pfizer Inc.
Date:________________________ _

By:
Ropes & Gray LLP
One International Place
Boston, MA 02110
Date:

DLA Piper LLP (US)
33 Arch Street, 26th Floor
Boston, MA 02110
Date:

_______________

MEMO
TO: DONNA HEAVENER
FROM: LINDA CONTI

CC: LAURIE SIMPSON, SANDRA HARPER
DATE: NOVEMBER 25, 208
RE: PFIZER SETTLEMENT 2008

Attached is a copy o f the court filings in State o f Maine v. Pfizer Inc. I have also attached the
settlement check in the amount o f $630,409. Please deposit $600,000 in the general fund. Please
deposit the balance o f $30,409 into the consumer and antitrust account. Thank-you.

14001

1140

Pfizer Inc

Vendor #

Voucher#

0000528191

Invoice#

0 1 2 8 2 1 9 8 4 EPAY18 2 6 9 7 2

Page:

1 OF 1

235 East 42nd Street
New Yorlc, NY 10017-5755

FOR INQUIRES CONCERNING THIS PAYMENT
TELEPHONE (901) 215-1111

115
24000115

Invoice Date

Invoice Amount

Discount

1 1 /1 8 /0 8

6 3 0 ,4 0 9 .0 0

0 .0 0

Net Amount
6 3 0 ,4 0 9 .0 0

I n t e r n a l R ef:E P A Y 1 8 2 6 9 7 2
L in d a C o n t i , A s s i s t a n t A t t o r n e y
G eneral
C onsum er P r o t e c t i o n D i v i s i o n

Stop waiting by the mailbox for your check. You may be eligible to receive payments
directly into your bank account. Email ACH@Pfizer.com to find out more about
Pfizer’s Electronic Payment (ACH) program.
You can now access your account information 24 hours a day, 7 days a week at
www.pfizeraccountspayable.com

C0KSÜMn,! |,ß<ITE, . r ,0wlj

R E C E IV E D

"

NOV 2 4
OFFICE OF ATI O m - .'r .Y C-'L-fT' ' •

0. 00

6 3 0 ,4 0 9 .0 0

NY01 005923280

__

-\'

j‘__ ;______ . ¡si__ _
l ï $:V

6 3 0 ,4 0 9 .0 0

¿____ 5*___, _

NY01 005923280

Pfizer Inc

Pfizer Inc

66-49

New York, NY 10017-5755

Mo Day Year

Wachovia Bank N A
Gresnsboro, NC

I 11
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Pay Exactly: Six Hundred Thirty Thousand Four Hundred Nine Dollars And No Cents

08
Amount * * " * * 6 3 0 , 4 0 9 . 0 0
Pfizer Inc

To the Order of
0000528191

005923280

MAINE ATTORNEY GENERAL
109 SEWALL STREET
BURTON CROSS BUILDING
6TH FLOOR
AUGUSTA
ME 04333-0006
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Authorized Corporate Signatory
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R egional Offices.64 H arlow St ., 2n d Floor
B angor Maine 04401
T ed (207) 941-3070
Fa x .- (207) 941-3075

G. Steven R owe

44 Oak Street, 4th Floor
P ortland , Maine 04101-3014
T ed (207) 822-0260
Fa x (207) 822-0259
TDD (877) 428-8800

ATTORNEY GENERAL

S ta te of M a i n e
O f f i c e of t h e A t t o r n e y G e n e r a l
6 S tate H o u se S ta tio n
A u g u s t a , M a i n e 04333-0006

TEL: (207) 626-8800
TTY: 1-800-577-6690

128 Sweden St., St e 2
Caribou , Maine 04736
TED (207) 496-3792
Fax - (207) 496-3291

October 22, 2008

HAND DELIVERED

Michele Lumbert, Clerk
Kennebec County Superior Court
95 State Street
Augusta ME 04330
Re: State o f Maine

V.

Pfizer Inc

Dear Ms. Lumbert:
Enclosed for filing please find a Summary sheet, Complaint, Consent Judgment and an
Application for Transfer to Business and Consumer Docket.
Please bring this matter to the Court’s attention at your earliest convenience.
Sincerely,

LINDA J.
Assistant ahorney General
LJC/sm
Enclosures
C: Russell B. Pierce, Esq.

This summary sheet and the information contained herein neither replace nor supplement the tiling and service of pleadings or other papers as
^•required by the Maine Rules o f Court or by law. This form is required for the use of the Clerk o f Court for the purpose o f initiating or
updating the civil docket. (SEE INSTRUCTIONS ON REVERSE)____________________________________________________________
I.

C o u n t y o f F i l i n g or D i s t r i c t C o u r t J u r i s d i c t i o n :

II. CAUSE OF ACTION

KENNEBEC

(Cite the primary civil statutes under which you are filing, if any.) Pro se plaintiffs: I f unsure, leave blank.

Maine's Unfair Trade Practices Act (UTPA) 5 M.R.S.A. § 207
NATURE OF FILING
[71 Initial Complaint
1 1 Third-Party Complaint
1 1 Cross-Claim or Counterclaim
1 1 I f R e i n s t a t e d or R e o p e n e d c a s e , g i ve o r i g in a l D o c k e t N u m b e r

III.

(If filing a second or subsequent Money Judgment Disclosure, give docket number of first disclosure)
IV.

□

TITLE TO REAL ESTATE IS INVOLVED

MOST DEFINITIVE NATURE OF ACTION. (Place a n X in one box only )

V.

1 1
1 1
1 1
]
]
1 1
]
]
]
]
]
]

Personal Injury Tort
Property Negligence
Auto Negligence
Medical Malpractice
Product Liability
Assault/Battery
Domestic Torts
Other Negligence
Other Personal Injury Tort
Non- Personal Injury Tort
Libel/Defamation
Auto Negligence
Other Negligence
Other Non-Personal Injury Tort

□
□
□
□
□

□
□
□

Pro se plaintiffs: If unsure, leave blank.

GENERAL CIVIL (CVf
Contract
□
Contract
□
Dec larat ory/ Equit able Reli ef
□
General Injunctive.Relief
□
Declaratory Judgment
□
Other Equitable Relief
□
C o n s t i t u t i o n a l / C i v i l Rights
□
Constitutional/Civil Rights
□
S t a t ut or y Actions
□
Unfair Trade Practices
□
Freedom of Access
□
Other Statutory Actions
□
M i s c e l l a n e o u s Civil
□
Drug Forfeitures
□
CHILD PROTECTIVE CUSTODY (PC)

Other Forfeitures/Property Libels
Land Use Enforcement (80K)
Administrative Warrant
HIV Testing
Arbitration Awards
Appointment of Receiver
Shareholders' Derivative Actions
Foreign Deposition
Pre-action Discovery
Common Law Habeas Corpus
Prisoner Transfers
Foreign Judgments
Minor Settlements
Other Civil

] Non-DHS Protective Custody
SPECIAL ACTIONS ISA!
Mo ne y Judgment
] Money Judgment Request Disclosure

1 1
]
]
1 1

T i t l e A c t io ns
Quiet Title
Eminent Domain
Easements
Boundaries

1 1 Governmental Body (80B)
VI.

REAL ESTATE IRE!
Mise. Real Estate
Foreclosure
Equitable Remedies
Foreclosure for Non-pmt (ADR exempt)
□
□
Mechanics Lien
Foreclosure - Other
□
□
Partition
Trespass
□
Adverse
Possession
Trespass
□
□
APPEALS ( A PI ITo be filed in Superior Court! (ADR exempt)
Other Appeals
Administrative Agency (80C)
□
□

] Nuisance
] Abandoned Roads
1 1 Other Real Estate

M . R . C i v . P . 16B A l t e r n a t i v e D i s p u t e R e s o l u t i o n ( A D R ) :

□

I certify that pursuant to M.R.Civ.P. 16B(b), this case is exempt from a required ADR process because:
□
It falls within an exemption listed above (i.e., an appeal or an action for non-payment of a note in a secured transaction).
□
The plaintiff or defendant is incarcerated in a local, state or federal facility.
□
The parties have participated in a statutory prelitigation screening process with_____________________________________
(name of neutral) o n ___________________________________ (date).
□
The parties have participated in a formal ADR process with _____________________________________ (name of neutral)
o n ___________________________________ (date).
□
This is a Personal Injury action in which the plaintiffs likely damages will not exceed $30,000, and the plaintiff requests an
___________ exemption from ADR._____________________________________________________________________________________

CV-001. Rev. 01/0?.

| VII. ( a ) [ 3 PLAINTIFFS (Name & Address including county)
or O Third-Party, Q Counterclaim or Cross-Claim Plaintiffs
□ The plaintiff is a prisoner in a local, state or federal facility.

State of Maine

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number) I f all counsel listed do N O T represent all plaintiffs,
( I f p r o s e plaintif f , leave blank)
.
specify who the listed attorney(s) represent.

Linda J. Conti, ME Bar No.3638
Assistant Attorney General
Office of Attorney General
6 State House Station
Augusta ME 04330
(207) 626-8591
VIII. (a)t7l DEFENDANTS fName & Address including county)
and/or Q Third-Party, Q Counterclaim or Q Cross-Claim Defendants
□ The defendant is a prisoner in a local, state or federal facility.

PFIZER Inc

I f all counsel listed do NOT represent all
d ef en da n t s , specify who the listed attorney(s)
represent.

(b) Attorneys (Name, Bar number, Firm name, Address, Telephone Number)
(If known)

Russell B. Pierce, Jr. Esq. ME Bar No. 7322
Norman Hanson & DeTroy, LLC
415 Congress Street
PO Box 4600
Portland, ME 04112

IX.

RELATED CASE(S) IF A N Y __________________________________________
Assigned Judge/Justice____________________________
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y or Pro se Party
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V.

PFIZER INC
DEFENDANT

CONSENT JUDGMENT

)
)
)
)

1.
The parties voluntarily enter into this Consent Judgment on the terms and
conditions set forth below.
Definitions:
a.

“Covered Conduct” shall mean Pfizer’s promotional and marketing

practices regarding the prescription drugs Celebrex® and Bextra®, that were the subject
o f an investigation by the Signatory Attorneys General under the State Consumer
Protection Laws.
b.

“Effective Date” shall mean the date by which Pfizer and ninety percent

(90%) of the States that comprise the M ultistate Working Group have executed the
Consent Judgment.
c.

“FDA Amendments Act o f 2007” (or “FDA Amendments Act” or “the

Act”) shall mean Public Law No. 110-85, which among other things, creates a federal
clinical trial registry and results data bank.
d.

“FD A ’s Guidance for Industry” shall mean documents published by the

United States Department of Health and Human Services, Food and Drug Administration
(FDA), that represent the FDA’s current recommendations on atopic.

e.

“Individual States” and “ State” shall mean each Signatory Attorney

General who is participating in the Multistate Working Group.
f.

“Pfizer” shall mean Pfizer Inc and its United States-based affiliates,

subsidiaries, predecessors, successors, and assigns.
g.

“Multistate Executive Committee” shall mean the Attorneys General and

their staffs representing Arizona, California, Florida, Illinois, Massachusetts, New York,
Ohio, Oregon, Texas, and Vermont.
h.

“Multistate Working Group” (“MSWG”) shall mean the Attorneys

General and their staffs representing Alaska, Arizona, Arkansas, California, Connecticut,
Florida, District o f Columbia, Idaho, Illinois, Iowa, Kansas, Kentucky, Maine, Maryland,
Massachusetts, Michigan, Montana, Nebraska, Nevada, New Jersey, New Mexico, New
York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, South Carolina, South
Dakota, Tennessee, Texas, Vermont, Washington, and Wisconsin.
i.

“Off-Label” shall mean related to an indication that was not approved by

the FDA at the time of dissemination or relating to information that was not contained in
the FDA label.
j.

“Prescriber” shall mean any physician, dentist, physician assistant, nurse

practitioners, and all others with legal authority to prescribe any Pfizer product, as well as
pharmacists, members of Pharmacy ¿¿Therapeutics committees and others who
potentially have an impact on the prescribing of any Pfizer product.
k.

“Parties” shall mean Pfizer and the Individual States.
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l.

“Product” shall mean any prescription drug or biological product

manufactured, distributed, sold, marketed or promoted in the United States in any way.
m.

“Signatory Attomey(s) General” shall mean the Attorney General, or his

or her designee, o f each state in the Multistate Working Group.
n.

“State Consumer Protection Laws” shall mean the consumer protection

laws under which the Signatory Attorneys General have conducted their investigation.1

1 The States’ consumer protection statutes are: ALASKA - Unfair Trade Practices and
Consumer Protection Act, AS 45.50.471 et seq.; ARIZONA - Consumer Fraud Act,
A.R.S. § 44-1521 et seq:, ARKANSAS - Ark. Code Ann. § 4-88-101 et seq:,
CALIFORNIA - Bus. & Prof. Code §§ 17200 et seq. and 17500 et seq:, CONNECTICUT
- Conn. Gen. Stat. §§ 42-110a et seq:, DISTRICT OF COLUMBIA - Consumer
Protection Procedures Act, D.C. Code § 28-3901 et seq:, FLORIDA - Deceptive and
Unfair Trade Practices Act, Fla. Stat. Ch. 501.201 et seq:, IDAHO - Consumer
Protection Act, Idaho Code Section § 48-601 et seq:, ILLINOIS - Consumer Fraud and
Deceptive Business Practices Act, 815 ILCS § 505/1 et seq. (2006 State Bar Edition);
IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16; KANSAS - Consumer
Protection Act, K.S.A. 50-623 et seq:, KENTUCKY - Consumer Protection Statute, KRS
367.110 et seq.; MAINE - Unfair Trade Practices Act, 5 M.R.S.A. § 207 et seq.;
MARYLAND - Consumer Protection Act, Md. Code Ann., Com. Law § 13-101 et seq.;
MASSACHUSETTS - Consumer Protection Act, M.G.L. c. 93A et seq:, MICHIGAN Michigan Consumer Protection Act, MCL 445.901 et seq.; MONTANA - Mont. Code
Ann. § 30-14-101 et seq.; NEBRASKA - Uniform Deceptive Trade Practices Act, NRS
§ 87-301 et seq.; NEW JERSEY - New Jersey Consumer Fraud Act, 56:8-1 et se#.; NEW
YORK - General Business Law Article 22-A Sections 349, 350 and Executive Law
Section 63 (12); NEW MEXICO - Unfair Practices Act, NMSA 1978, § 57-12-1 et seq.;
NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.;
NORTH CAROLINA - Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. § 751.1 et seq.; NORTH DAKOTA - Unlawful Sales or Advertising Practices, N.D. Cent. - .
Code. § 51-15-02 et seq.; OHIO - Consumer Sales Practices Act, R.C. 1345.01 et seq.;
OREGON - Unlawful Trade Practices Act, ORS 646.605 to 646.656; PENNSYLVANIA
- Unfair Trade Practices and Consumer Protection Law, 73 P.S. § 201-1 et seq.; SOUTH
CAROLINA - Unfair Trade Practices Act, S.C. CODE. ANN. Sections 39-5-10 et seq.;
SOUTH DAKOTA - Deceptive Trade Practices Act, S.D. Codified Laws § 37-24 et seq.;
TENNESSEE - Consumer Protection Act, Tenn. Code Ann. §§ 47-18-101 et seq.;
TEXAS - Deceptive Trade Practices - Consumer Protection Act, Tex. Bus. and Com.
Code § 17.47 et seq.; VERMONT - Consumer Fraud Act, 9 V.S.A. § 2451 et seq.;
WASHINGTON - Unfair Business Practices/Consumer Protection Act, R.C.W. 19.86 et
-3-

o.

“Celebrex” shall mean celecoxib.

p.

“Bextra” shall mean valdecoxib.
2.

The parties have agreed to resolve the issues raised by the Covered Conduct by
entering into this Consent Judgment (hereinafter “Judgment”).
(a)

Pfizer is entering into this Judgment solely for the purpose of settlement,

and nothing contained herein may be taken as or construed to be an admission or
concession o f any violation o f law, rule, or regulation, or o f any other matter of fact or
law, or o f any liability or wrongdoing, all of which Pfizer expressly denies. Pfizer does
not admit any violation o f the State Consumer Protection Laws set forth in footnote 1,
and does not admit any wrongdoing that was or could have been alleged by any Attorney
General before the date o f the Judgment under those laws. No part o f this Judgment,
including its statements and commitments, shall constitute evidence of any liability, fault,
or wrongdoing by Pfizer. This document and its contents are not intended for use by any
third party for any purpose, including submission to any court for any purpose.
(b)

This Judgment shall not be construed or used as a waiver or limitation of

any defense otherwise available to Pfizer in any action, or of Pfizer’s right to defend itself
from, or make any arguments in, any private individual, regulatory, governmental, or
class claims or suits relating to the subject matter or terms of this Judgment. This
Judgment is made without trial or adjudication of any issue of fact or law or finding of
liability o f any kind. Notwithstanding the foregoing, a State may file an action to enforce
the terms o f this Judgment.

seq:, WISCONSIN - Wis. Stat. § 100.18 et seq,. (Fraudulent Representations) and Wis.
Stat. § 100.182 et seq. (Fraudulent Drug Advertising).
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(c)

It is the intent of the Parties that this Judgment not be admissible in other

cases or binding on Pfizer in any respect other than in connection with the enforcement of
this Judgment.
(d)

No part of this Judgment shall create a private cause o f action or confer

any right to any third party for violation of any federal or state statute except that a State
may file an action to enforce the terms o f this Judgment.
(e)

All obligations undertaken by Pfizer in this Judgment shall apply

prospectively, except to the extent permitted by the National Library of Medicine, Pfizer
shall submit, as soon as practicable, clinical trial results to the clinical trial registry and
results data bank created by the FDA Amendments Act for all “applicable clinical trials”
(as that term is defined by the Act) of FDA-approved Pfizer Products that were initiated
after July 1, 2005.
3.
Pfizer shall register clinical trials and submit results to the registry and results
data bank as required by the FDA Amendments Act and any accompanying regulations
that may be promulgated pursuant to that Act.
4.
Pfizer shall not make any written or oral claim that is false, misleading or
deceptive regarding any FDA-approved Pfizer Product.
5.
Pfizer shall not make any written or oral promotional claims of safety or
effectiveness for any FDA-approved Pfizer Product in a manner that violates the Food,
Drug and Cosmetic Act, 21 U.S.C. § 301 et seq. (“FDCA”), accompanying regulations,
or voluntary agreements with FDA, as interpreted by the FDA in a writing by the
Director of the Center for Drug Evaluation at the FDA.
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6.
Nothing in this Judgment shall require Pfizer to:
(a)

take an action that is prohibited by the FDCA or any regulation

promulgated thereunder, or by FDA; or
(b)

fail to take an action that is required by the FDCA or any

regulation promulgated thereunder, or by FDA. Any written or oral promotional claim
subject to this Judgment which is the same, or materially the same, as the language
required or agreed to by the Director of Division o f Drug Marketing, Advertising and
Communication or the Director o f the Center for Drug Evaluation and Research or their
authorized designees in writing shall not constitute a violation of this Judgment.
7.
Following the initial approval of any Pfizer Product indicated for pain relief,
Pfizer shall delay direct to consumer (“DTC”) television advertising that relates to such
indication, if the Director of the Center for Drug Evaluation and Research at FDA
recommends such a delay in writing to Pfizer. Pfizer’s delay shall be for the same period
as recommended by the Director of the Center for Drug Evaluation and Research at FDA,
but in no event shall the period o f delay required by this provision o f this Judgment
exceed 18 months from approval. Should Pfizer run television DTC advertising contrary
to a recommendation from the Director o f the Center for Drug Evaluation and Research
after the expiration o f this 18 month period, Pfizer shall provide written notice to the
Multistate Executive Committee 30 days prior to running the subject advertisement and
shall also provide a copy o f all correspondence with FDA relating to the subject
advertisement.

8.
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Pfizer agrees to submit all new DTC television advertising campaigns for any
Pfizer Product to FDA for pre-review, to wait a reasonable time (not less than 45 days)
until Pfizer receives a response from FDA prior to running the advertising campaign,
and to modify such advertising consistent with any written comments from FDA,
whenever received. Simultaneous with running any new DTC television advertisement
for which FDA has not provided Pfizer with a pre-review response addressing the
substance o f the advertisement within the 45-day waiting period prescribed herein,
Pfizer shall provide written notice to the Multistate Executive Committee that Pfizer is
running the advertisement and that the FDA has not provided Pfizer with a pre-review
response addressing the substance o f the advertising within the 45-day waiting period,
and also provide a copy of all material submitted to FDA for the review of the subject
advertisement.
9.
Pfizer’s obligations with respect to Paragraph 7 shall remain in effect for eight
years following the Effective Date. Pfizer’s obligations with respect to Paragraph 8 shall
remain in effect for seven years following the Effective Date. With respect to
Paragraph 7, Pfizer shall abide by any such written recommendation so long as the
submission o f the TV advertising campaign is made within eight years following the
Effective Date. With respect to Paragraph 8, Pfizer shall abide by any such written
recommendation so long as the submission o f the TV advertising campaign is made
within seven years o f the Effective Date.
10.
W hen presenting information in detailing pieces, brochures, booklets, mailing
pieces, published journals, magazines, other periodicals and newspapers, and broadcast
through media such as radio, television, the Internet, and telephone communications
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systems, about a Clinical Study that relates to an FDA-approved Pfizer Product, Pfizer
shall: (a) accurately reflect the methodology used to conduct the Clinical Study; (b) not
present favorable information or conclusions from a study that is inadequate in design,
scope, or conduct to furnish significant support for such information or conclusions; and
(c) not use statistical analyses and techniques on a retrospective basis to discover and cite
findings not soundly supported by the study, or to suggest scientific validity and rigor for
data from studies the design or protocol o f which are not amenable to formal statistical
evaluations.
11.
When presenting information in detailing pieces, brochures, booklets, mailing
pieces, published journals, magazines, other periodicals and newspapers, and broadcast
through media such as radio, television, the Internet, and telephone communications
systems, about a Clinical Study or analysis o f Clinical Studies as evidence o f an FDAapproved Pfizer Product’s safety, Pfizer shall not: (a) present information from a study in
a way that implies that the study represents larger or more general experience with the
drug than it actually does; or (b) use statistics on numbers o f patients, or counts of
favorable results or side effects derived from pooling data from various insignificant or
dissimilar studies in a way that suggests either that such statistics are valid if they are not
or that they are derived from large or significant studies supporting favorable conclusions
when such is not the case.
12.
When presenting information in detailing pieces, brochures, booklets, mailing
pieces, published journals, magazines, other periodicals and newspapers, and broadcast
through media such as radio, television, the Internet, and telephone communications
systems, about a Clinical Study or analysis of Clinical Studies as evidence o f an FDA-
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approved Pfizer Product’s safety, Pfizer shall not: (a) present favorable information or
conclusions from a study that is inadequate in design, scope, or conduct to furnish
significant support for such information or conclusions; (b) use the concept o f statistical
significance to support a claim that has not been demonstrated to have clinical
significance or validity, or fails to reveal the range o f variations around the quoted
average results; or (c) use statistical analyses and techniques on a retrospective basis to
discover and cite findings not soundly supported by the study, or to suggest scientific
validity and rigor for data from studies the design or protocol o f which are not amenable
to formal statistical evaluation.
13.
(a)

Pfizer shall comply with the ACCME Standards for Commercial

Support (a copy o f the current version is attached hereto as Appendix 1).
(b)

Any person who acts in a promotional capacity for Pfizer with respect to

an FDA approved Pfizer Product shall be obligated under his or her contract with Pfizer,
as a condition for any future promotional relationship with Pfizer, to disclose to
Continuing Medical Education (“CM E”) participants orally and to the CME provider for
inclusion in the written materials the existence, nature and purpose of his or her
arrangement with Pfizer when a member o f the faculty at a CME program if: (i) the
Product the faculty member promoted for Pfizer is in the same therapeutic category as
the subject o f the CME program, and (ii) the CME program occurs within 12 months of
the faculty member performing work for or receiving compensation from Pfizer. Such
disclosure shall set forth the type o f promotional work engaged in by the faculty member
and the name o f the therapeutic category with respect to such promotion.
(c)

Pfizer shall not provide funding for CME when Pfizer has knowledge at

the time the decision to fund the CME is made that a speaker at the CME has also been a
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promotional speaker in the past 12 months at a Pfizer-sponsored promotional event
related to the class of drugs to be discussed in the CME.

14.
Pfizer’s obligations with respect to CME shall remain in effect for 9 years
following the Effective Date. Pfizer’s obligations with respect to Paragraph 13(b) shall
only apply to speakers’ contracts entered into, amended to extend the contract period, or
renewed after the date o f this Judgment.
15.
Pfizer shall require all individuals who are named as authors on a Pfizersponsored manuscript reporting the results of a Pfizer-sponsored study to fulfill the
following conditions: (a) the individual shall have made a substantial contribution to the
conception and design, or acquisition o f data, or analysis and interpretation of data; (b)
the individual shall have been involved in drafting the article or revising it critically for
important intellectual content; and (c) the individual shall have final approval rights of
the version to be published. W hen a large, multi-center group has conducted the
research, the manuscript shall identify the individuals who accept direct responsibility for
the manuscript. These individuals should fully meet the criteria for authorship as set
forth in (a), (b), and (c) above.
16.
Pfizer shall not disseminate in a promotional context any patient testimonial relating
to a Product that does not clearly and conspicuously disclose what the generally expected
performance would be in the depicted circumstances or clearly and conspicuously
disclose the limited applicability of the experience described by the patient testimonial to
what consumers may generally expect to achieve.
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17.

Pfizer shall not market two or more Products in a manner that falsely or misleadingly
conflates the various properties of the respective Products.
18.
Pfizer shall not compensate physicians for conducting individual, observational
teaching sessions in their offices or in the hospital (“mentorships”) in which sales
representatives who detail a Product participate.
19.
Pfizer shall instruct investigators of Pfizer sponsored clinical trials regarding a
Product to obtain a legally effective informed consent from all study subjects or from the
subject’s legally authorized representative. If Pfizer provides the investigator (or the
investigator’s Institutional Review Board) with a model informed consent, Pfizer shall
not fail to include (a) a statement that the study involves research, an explanation of the
purposes o f the research and the expected duration o f the subject’s participation, a
description o f the procedures to be followed, and identification o f any procedures which
*• . are experimental; (b) a description of any reasonably foreseeable risks or discomforts to
the subject; and (c) for research involving more than minimal risk, an explanation as to
whether any compensation and an explanation as to whether any medical treatments are
available if injury occurs and, if so, what they consist of, or where further information
may be obtained.
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20.

Pfizer shall not affirmatively seek the inclusion o f a Product in hospital protocols or
standing orders unless the Product at issue has been approved by the FDA for the
indication for which it is to be included in the protocol or standing order.
Notwithstanding the foregoing, Pfizer may disclose to insurance companies and other
third party payors any information regarding the inclusion o f a Product in hospital
protocols or standing orders even if the Product at issue has not been approved by the
FDA for the indication for which it is to be included in the protocol or standing order.
21 .
Pfizer shall not award prizes or other incentives to its sales force as rewards for
specifically increasing the Off-Label use o f a Product.

22.
Pfizer shall not disseminate any information describing any Off-Label use o f a
Product if such use has been submitted to the FDA for approval and the FDA has either
advised Pfizer that it refuses to approve such application or that FDA-identified
deficiencies must be resolved before approval can be granted unless Pfizer has first
clearly and conspicuously disclosed to the information recipient that FDA had issued
such advice regarding such Off-Label use. Pfizer may disclose to any recipient of such
information whether the information was presented to the FDA prior to the FDA’s
issuance of such advice regarding the Off-Label use.
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23.

Pfizer shall not disseminate a Medical Information Letter, an unabridged reprint or
copy of an article from a Peer Reviewed Journal or a Reference Publication, or written
information through a Regional Medical Research Specialist (“RMRS”) describing any
Off-Label use o f a Product in response to an unsolicited request by a prescriber or other
health care professional unless (a) the information is about a clinical investigation with
respect to the Product and experts qualified by scientific training or experience to
evaluate the safety or effectiveness o f the Product would consider the subject of the
clinical investigation to be scientifically sound or the information is an unabridged reprint
or copy o f an article from a Peer Reviewed Journal or a Reference Publication; (b) the
information is accompanied by a comprehensive bibliography of publications discussing
adequate and well-controlled clinical studies published in a medical journal or medical or
scientific text that have been previously published about the use of the Product covered
by the information (unless the information is a Peer Reviewed Journal or Reference
Publication which already includes such a bibliography); and (c) in cases in which
experts qualified by scientific training or experience to evaluate the safety or
effectiveness of the Product would consider the conclusion o f the information to have
been specifically called into question by another article(s) or text(s) that experts qualified
by scientific training or experience to evaluate the safety or effectiveness of the Product
would consider to be scientifically sound, the information must be disseminated with a
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representative publication that reaches contrary or different conclusions regarding the
Off-Label use.
24.
Pfizer shall not disseminate any reprint or copy o f an article from a Peer Reviewed
Journal or a Reference Publication describing any Off-Label use of the Product to
physician specialties that do not customarily prescribe the Product if these materials
combined with detailing, advertising, sampling, or other promotional activities promote
Off-Label use o f the Product.
25.
In the event that FDA issues a final “Guidance For Industry: Good Reprint Practices
For The Distribution O f Medical Journal Articles And Medical Or Scientific Reference
Publications On Unapproved New Uses O f Approved Drugs And Approved Or Cleared
Medical Devices,” and a provision o f said Guidance materially conflicts with any o f the
provisions of Paragraphs 22 through 24 o f this Judgment, Pfizer may petition the Court
for modification of those paragraphs, after providing thirty (30) days’ notice to the
Attorney General. The parties by stipulation may agree to such a modification, which
agreement shall be presented to this Court for consideration provided that the parties may
jointly agree to a modification only by a written instrument signed by or on behalf o f both
Pfizer and the Attorney General. If Pfizer wishes to seek a stipulation for a modification
from the State, it shall send a written request for agreement to such modification to the
Attorney General at least 30 days prior to filing a motion with the Court for such
modification. Within 30 days o f receipt from Pfizer o f a written request for agreement to
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modify, the Attorney General shall notify Pfizer in writing if the Attorney General agrees
to the requested modification. The Attorney General shall not unreasonably withhold
his/her consent to the modification. The parties agree it would be unreasonable to
withhold consent to the terms provided in the draft “Guidance For Industry: Good
Reprint Practices For The Distribution O f Medical Journal Articles And Medical Or
Scientific Reference Publications On Unapproved New Uses O f Approved Drugs And
Approved Or Cleared Medical Devices,” dated February 15, 2008, and attached hereto as
Appendix 2, in the event that all such terms are included in the final Guidance For
Industry. In the event that all such terms are not included in the final Guidance for
Industry, the parties agree to consider whether any such terms that are included in the
final Guidance for Industry should form the basis o f a modification o f Paragraphs 22
through 24 of this Judgment.
26.
Pfizer shall not disseminate any Medical Information Letter describing any Off-Label
use of a Product that makes any false or misleading representation regarding a Product.
27.
Pfizer shall not disseminate samples o f a Product with the intent o f increasing
Off-label prescribing o f the Product.
28.
When submitting clinical trials relating to Off-label indications to journals for
publication, Pfizer shall disclose to the journal that the FDA has not approved the drug
for the indication that was the subject of the clinical trial.
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29.
The Pfizer Medical Education Grants Office shall manage all requests for funding
related to CME regarding Products. Approval decisions shall be made by the Pfizer
Medical Education Grants Office alone, and shall be kept separate from the Sales and
Marketing function. Notwithstanding the foregoing, decisions to approve a request for
funding made by the Pfizer Medical Education Grants Office may be subject to actual
funding approval by Pfizer’s Chief Financial Officer or other designated officials.
30.
Pfizer shall not use grants to advantage or promote Products. This provision includes,
but is not limited to, the following prohibitions:
(a)

Sales and Marketing personnel shall not initiate, coordinate or
implement grant applications on behalf of any customer or
Prescriber;

(b)

Sales and Marketing personnel shall not be involved in selecting
grantees or CME-funded speakers; and

(c)

Sales and Marketing personnel shall not measure or attempt to
track in any way the impact o f grants or speaking fees on the
participating Prescribers’ subsequent prescribing habits, practices
or patterns.
31.

Pfizer Sales and Marketing personnel shall not approve grant requests regarding
Products, nor attempt to influence the Pfizer Medical Education Grants Office to reward
any customers or Prescribers with grants for their prescribing habits, practices or patterns.
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32.

By its execution of this Judgment, State o f Maine releases Pfizer and all of its past
and present subsidiaries, affiliates, predecessors and successors (collectively, the
“Released Parties”) from the following: all civil claims, causes o f action, damages,
restitution, fines, costs, and penalties on behalf o f the State of Maine under the abovecited consumer protection statutes arising from the Covered Conduct that is the subject of
this Judgment.
33.
Notwithstanding any term o f this Judgment, specifically reserved and excluded
from the Release in Paragraph 32 as to any entity or person, including Released Parties,
are any and all o f the following:
(a)

Any criminal liability that any person or entity, including Released Parties,

has or may have to the State o f Maine.
(b)

Any civil or administrative liability that any person or entity, including

Released Parties, has or may have to the State o f Maine not expressly covered by the
release in Paragraph 32 above, including but not limited to any and all o f the following
claims:
i)

State or federal antitrust violations;

ii)

Reporting practices, including “best price”, “average wholesale '

price” or “wholesale acquisition cost;”
iii)

Medicaid violations, including federal Medicaid drug rebate statute

violations, Medicaid fraud or abuse, and/or kickback violations related to any
State’s Medicaid program; and,
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iv)
(c)

State false claims violations.

Any liability under the State o f M aine’s above-cited consumer protection

laws which any person or entity, including Released Parties, has or may have to
individual consumers or State program payors o f said State, and which have not been
specifically enumerated as included herein.
(d)

Any liability for failure to comply with M aine’s Prescription Drug Clinical

Trial Reporting Rule: DHS Rule 10-144 Ch. 275, AG rule 26-0259 Ch. 11 with respect
to any drug other than Celebrex and Bextra.
34.
Within ten (10) days o f the Effective Date o f this Judgment, Pfizer shall pay a
total amount o f sixty million dollars ($60,000,000) to be divided and paid by Pfizer
directly to each Signatory Attorney General in an amount to be designated by and in the
sole discretion o f the Multistate Executive Committee. Said payment shall be used by the
States for attorneys’ fees and other costs o f investigation and litigation, or to be placed in,
or applied to, the consumer protection enforcement fund, consumer education, litigation
or local consumer aid fund or revolving fund, used to defray the costs of the inquiry
leading hereto, or for other uses permitted by state law, at the sole discretion o f each
Signatory Attorney General.
35.
For the purposes o f resolving disputes with respect to compliance with this
Judgment, should any of the Signatory Attorneys General have a reasonable basis to
believe that Pfizer has engaged in a practice that violates a provision of this Judgment
subsequent to the Effective Date of this Judgment, then such Attorney General shall
notify Pfizer in writing of the specific objection, identify with particularity the provisions
of this Judgment that the practice appears to violate, and give Pfizer thirty (30) days to
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respond to the notification; provided, however, that a Signatory Attorney General may
take any action if the Signatory Attorney General concludes that, because o f the specific
practice, a threat to the health or safety o f the public requires immediate action.
Upon receipt o f written notice, Pfizer shall provide a good-faith written response
to the Attorney General notification, containing either a statement explaining why Pfizer
believes it is in compliance with the Judgment, or a detailed explanation of how the
alleged violation occurred and a statement explaining how Pfizer intends to cure the
alleged breach. Nothing in this paragraph shall be interpreted to limit the state's Civil
Investigative Demand (“CID”) or subpoena authority, to the extent such authority exists
under applicable state law, and Pfizer reserves all o f its rights with respect to a CID or
subpoena issued pursuant to such authority.
36.
Upon giving Pfizer thirty (30) days to respond to the notification described above,
the Signatory Attorney General shall also be permitted reasonable access to inspect and
copy relevant, non-privileged, non-work product records and documents in the
possession, custody or control o f Pfizer that relate to Pfizer’s compliance with each
provision o f this Judgment as to which cause that is legally sufficient in the State has
been shown. If the Signatory Attorney General makes or requests copies o f any
documents during the course of that inspection, the Signatory Attorney General will
provide a list o f those documents to Pfizer.
37.
The State may assert any claim that Pfizer has violated this Judgment in a separate
civil action solely to enforce compliance with this Judgment, or to seek any other relief
afforded by law, but only after providing Pfizer an opportunity to respond to the
notification described in Paragraph 35 above; provided, however, that a Signatory
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Attorney General may take any action if the Signatory Attorney General concludes that,
because o f the specific practice, a threat to the health or safety o f the public requires
immediate action.
38.
This Judgment represents the full and complete terms o f the settlement entered
into by the parties hereto. In any action undertaken by either the Attorneys General, or
any o f them, or Pfizer, no prior versions o f this Judgment, and no prior versions of any of
its terms, that were not entered by the Court in this Judgment, may be introduced for any
purpose whatsoever.
IT IS SO STIPULATED:
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ACCME STA N D A R D S
FOR C O M M E R C IA L
S U P P O R T SM
Standards to Ensure the

Independence of CME
Activities

ACCME

T h e A C C M E S t a n d a r d s f o r C o m m e r c i a l S u p p o r t SM

Standards to Ensure Independence in CME Activities
S T A N D A R D 1:

In d e p e n d e n ce

1.1 A CME provider must ensure that the following
decisions were made free of the control of a
commercial interest. (See www.accme.org for
a definition of a 'commercial interest' and some
exemptions.)
(a)
(b)
(c)
(d)

Identification of CME needs;
Determination of educational objectives;
Selection and presentation of content;
Selection of all persons and organizations
that will be in a position to control the
content of the CME;
(e) Selection of educational methods;
(f) Evaluation of the activity.
1.2 A commercial interest cannot take the role of
non-accredited partner in a jo in t sponsorship
relationship.
S T A N D A R D 2 : R e so lu tio n of P e r s o n a l
C o n flic ts of In t e r e s t

2.1 The provider must be able to show that
everyone who is in a position to control the
content of an education activity has disclosed
all relevant financial relationships with any
commercial interest to the provider.
The
ACCME
defines
"'relevant'
financial
relationships" as financial relationships in any
amount occurring within the past 12 months
that create a conflict of interest.
2.2 An individual who refuses to disclose relevant
financial relationships will be disqualified from
being a planning committee member, a
teacher, or an author of CME, and cannot have
control
of,
or
responsibility
for,
the
development, management, presentation or
evaluation of the CME activity.
2.3 The provider must have implemented a
mechanism to identify and resolve all conflicts
of interest prior to the education activity being
delivered to learners.

I

3.3 All commercial support associated with a CME
activity must be given with the full knowledge
and approval of the provider.
W ritte n a g re e m e n t d o cu m e n tin g te rm s o f su p p o rt

3.4 The terms, conditions, and purposes of the
commercial support must be documented in a
written agreement between the commercial
supporter that includes the provider and its
educational partner(s). The agreement must
include the provider, even if the support is
given directly to the provider's educational
partner or a jo in t sponsor.
3.5 The written agreement must specify the
commercial interest that is the source of
commercial support.
3.6 Both the commercial supporter and the
provider must sign the written agreement
between the commercial supporter and the
provider.
E x p e n d itu re s fa r an in d iv id u a l p ro v id in g CME

3.7 The provider must have written policies and
procedures
governing
honoraria
and
reimbursement of out-of-pocket expenses for
planners, teachers and authors.
3.8 The provider, the jo in t sponsor, or designated
educational partner must pay directly any
teacher or author honoraria or reimbursement
of out-of-pocket expenses in compliance with
the provider's written policies and procedures.
3.9 No other payment shall be given to the director
of the activity, planning committee members,
teachers or authors, jo in t sponsor, or any
others involved with the supported activity.
3.10 If teachers or authors are listed on the
agenda as facilitating or conducting a
presentation or session, but participate in the
remainder of an educational event as a learner,
their expenses can be reimbursed and
honoraria can be paid for their teacher or
author role only.

S T A N D A R D 3 : A p p r o p r i a t e U s e of
C o m m e rc ia l S u p p o rt

E x p e n d itu re s for le a rn e rs

3.1 The provider must make all decisions regarding
the disposition and disbursement of commercial
support.

3.11 Social events or meals at CME activities
cannot compete with or take precedence over
the educational events.

3.2 A provider cannot be required by a commercial
interest to accept advice or services concerning
teachers, authors, or participants or other
education matters, including content, from a
commercial
interest
as
conditions
of
contributing funds or services.
ACCME®
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3.12 The provider may not use commercial support
to pay for travel, lodging, honoraria, or
personal expenses for non-teacher or non
author participants of a CME activity.
The
provider may use commercial support to pay
for travel, lodging, honoraria, or personal
expenses for bona fide employees and
volunteers of the provider, jo in t sponsor or
educational partner.
A c c o u n ta b ility

3.13 The provider must be able to produce
accurate documentation detailing . the receipt
and expenditure of the commercial support.
S T A N D A R D 4 . A p p r o p r ia t e M a n a g e m e n t o f !
A s s o c ia t e d C o m m e r c ia l P r o m o t io n

4.1 Arrangements for commercial exhibits or
advertisements cannot influence planning or
interfere with the presentation, nor can they be
a condition of the provision of commercial
support for CME activities.
4.2 Product-promotion material or product-specific
advertisement of any type is prohibited in or
during CME activities.
The juxtaposition of
editorial and advertising material on the same
products or subjects must be avoided. Live
(staffed exhibits, presentations) or enduring
(printed
or
electronic
advertisements)
promotional activities must be kept separate
from CME.
•

•

•

•

For print, advertisements and promotional materials will
not be interleafed within the pages of the CME content.
Advertisements and promotional materials may face the
fir s t or last pages of printed CME content as long as
these materials are not related to the CME content they
face and are not paid fo r by the commercial supporters of
the CME activity.
For computer based, advertisements and promotional
materials will not be visible on the screen a t the same
time as the CME content and not interleafed between
computer 'windows' or screens of the CME content
For audio and video recording, advertisements and
promotional materials will not be included within the CME.
There will be no 'commercial breaks.'
For live, face-to-face CME, advertisements and
promotional materials cannot be displayed or distributed
in the educational space immediately before, during, or
a fte r
a CME activity. Providers
cannot allow
representatives of Commercial Interests to engage in
sales or promotional activities while in the space or place
of the CME activity.

4.3 Educational materials that are part of a CME
activity, such as slides, abstracts and handouts,
cannot contain any advertising, trade name or
a product-group message.

4.4 Print or electronic information distributed about
the non-CME elements of a CME activity that
are not directly related to the transfer of
education to the learner, such as schedules and
content descriptions, may include productpromotion
material
or
product-specific
advertisement.
4.5 A provider cannot use a commercial interest as
the agent providing a CME activity to learners,
e.g., distribution of self-study CME activities or
arranging for electronic access to CME
activities.
S T A N D A R D 5. C o n t e n t and F o r m a t w it h o u t
C o m m e r c ia l B ia s

5.1 The content or format of a CME activity or its
related materials must promote improvements
or quality in healthcare and not a specific
proprietary business interest of a commercial
interest.
5.2 Presentations must give a balanced view of
therapeutic options. Use of generic names will
contribute to this impartiality.
If the CME
educational material or content includes trade
names, where available trade names from
several companies should be used, not ju s t
trade names from a single company. K
S T A N D A R D 6 .D is c lo s u r e s R e le v a n t to
P o t e n t ia l C o m m e rc ia l B ia s
R e le v a n t fin a n cia l re la tio n sh ip s o f th o se w ith co n tro l over
CWIE co n te n t

6.1 An individual must disclose to learners any
relevant financial relationship(s), to include the
following information:
•
•
•

The name of the individual;
The name of the commercial interest(s);
The nature of the relationship the person
has with each commercial interest.

6.2 For an individual with no relevant financial
relationship(s) the learners must be informed
that no relevant financial relationship(s) exist.
C o m m e rcia l su p p o rt for th e CME a ctivity .

6.3 The source of all support from commercial
interests must be disclosed to learners. When
commercial support is 'in-kind' the nature of
the support must be disclosed to learners.
6.4 'Disclosure' must never include the use of a
trade name or a product-group message.
T im in g o f d isc lo su re

6.5 A provider must disclose the above information
to learners prior to the beginning of the
educational activity. 3S
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Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles
and Medical or Scientific Reference Publications on Unapproved New Uses of Approved
Drugs and Approved or Cleared Medical Devices
This draft guidance document represents the Food and Drug Administration's current thinking on this topic. It
does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You
may use an alternative approach if the approach satisfies the requirements of the applicable statutes and
regulations. If you want to discuss an alternative approach, please contact the appropriate FDA staff.

I. Introduction
This draft guidance is intended to describe the Food and Drug Administration's (FDA or Agency) current
thinking regarding "Good Reprint Practices" with regard to the distribution of medical journal articles and
scientific or medical reference publications (referred to generally as medical and scientific information) that
discuss unapproved new uses for approved drugs1 or approved or cleared medical devices marketed in the
United States to healthcare professionals and healthcare entities.
FDA's guidance documents, including this draft guidance, do not establish legally enforceable rights or
responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed
only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word
should in Agency guidances means that something is suggested or recommended, but not required.

II.

Background

Section 401 of the Food and Drug Administration Modernization Act (FDAMA (21 U.S.C. § 360aaa, § 551,
Federal Food, Drug, and Cosmetic Act (FD&C Act))), described certain conditions under which a drug or
medical device manufacturer^ could choose to disseminate medical and scientific information discussing
unapproved uses of approved drugs and cleared or approved medical devices to healthcare professionals and
certain entities (including pharmacy benefits managers, health insurance issuers, group health plans, and
Federal or State governmental agencies). FDAMA section 401 provided that, if these conditions were met,
dissemination of such journal articles or reference publications would not be considered as evidence of the
manufacturer's intent that the product be used for an unapproved new use. FDA implementing regulations
were codified at 21 C.F.R. Part 99.
In 2000, subsequent to a decision by the United States Court of Appeals for the District of Columbia Circuit,
FDA published a Notice (65 Fed. Reg. 14286, March 16, 2000) clarifying the applicability of the FDAMA
section 401 provision and the FDA implementing regulations. In that Notice, FDA slated that the statute and
implementing regulations constituted a "safe harbor” for a manufacturer that complies with them before and
while disseminating journal articles and reference publications about “new uses" of approved or cleared
products. If a manufacturer complied with the FDAMA provision, the distribution of such journal articles or
reference publications would not be used as evidence of an intent that the product distributed by the
manufacturer be used for an unapproved use. The Notice stated that if a manufacturer chose to disseminate
materials but not proceed under FDAMA section 401, that failure would not constitute an independent violation
of law.
FDAMA section 401 ceased to be effective on September 30, 2006, and the implementing regulations are no
longer applicable. In light of the statute's sunset, FDA is providing its current views on the dissemination of
medical journal articles and medical or scientific reference publications on unapproved uses of approved
drugs and approved or cleared medical devices to healthcare professionals and healthcare entities.

III.

Purpose

As explained in FDA’s March 16, 2000 Notice, the FD&C Act and FDA's implementing regulations generally
prohibit manufacturers of new drugs or medical devices from distributing products in interstate commerce for
any intended use that FDA has not approved as safe and effective or cleared through a substantial
equivalence determination. (E.g., FD&C Act §§ 505(a), 502(o), 501(f)(1)(B), 301(a) and (d); 21 U.S.C. §§ 355,
352(o), 351(f)(1)(B), 331(a) and (d)). An approved new drug that is marketed for an unapproved use becomes
misbranded and an unapproved new drug with respect to that use. Similarly, a medical device that is
promoted for a use that has not been approved or cleared by FDA Is adulterated and misbranded.
FDA does, however, recognize the important public policy reasons for allowing manufacturers to disseminate
truthful and non-misleading medical journal articles and medical or scientific reference publications on
unapproved uses of approved drugs and approved or cleared medical devices to healthcare professionals and
healthcare entities. Once a drug or medical device has been approved or cleared by FDA, generally
healthcare professionals may lawfully use or prescribe that product for uses or treatment regimens that are not
included in the product's approved labeling (or, in the case of a medical device cleared under the 510(k)
process, in the product’s statement of intended uses). These off-label uses or treatment regimens may be
important and may even constitute a medically recognized standard of care. Accordingly, the public health
may be advanced by healthcare professionals' receipt of medical journal articles and medical or scientific
reference publications on unapproved or new uses of approved or cleared medical products that are truthful
and not misleading.
FDA's legal authority to determine whether distribution of medical or scientific information constitutes
promotion of an unapproved “new use,” or whether such activities cause a product to be misbranded or
adulterated has not changed. In recognition of the public health value to healthcare professionals of receiving
truthful and non-misleading scientific and medical information, FDA is providing recommendations concerning
"Good Reprint Practices" for the dissemination of medical journal articles and medical or scientific reference
publications on unapproved uses of drugs and medical devices.-

IV.

Agency Recommendations for Good Reprint Practices

Scientific and medical information that concerns the safety or effectiveness of an approved drug or approved
or cleared medical device for a new use that is not included in the product’s approved labeling or statement of
intended uses (including unapproved or new uses of approved drugs and approved or cleared devices) is
often published in journal articles or reference publications. These publications are often distributed by
manufacturers to healthcare professionals or healthcare entities. When a manufacturer disseminates such
medical and scientific information, FDA recommends that the following principles of “Good Reprint Practices"
be followed.
A.

Types of Reprints/Articles/Reference Publications

A scientific or medical journal article that Is distributed should:
• be published by an organization that has an editorial board that uses experts who have demonstrated
expertise in the subject of the article under review by the organization and who are independent of the
organization to review and objectively select, reject, or provide comments about proposed articles, and that
has a publicly stated policy, to which the organization adheres, of full disclosure of any conflict of interest or
biases for all authors, contributors, or editors associated with the journal or organization;
• be peer-reviewed and published in accordance with the peer-review procedures of the organization; and
• not be in the form of a special supplement or publication that has been funded in whole or In part by one or
more of the manufacturers of the product that is the subject of the article.
A scientific or medical reference publication that is distributed should not be:
• primarily distributed by a drug or device manufacturer, but should be generally available in bookstores or
other independent distribution channels where medical textbooks are sold;
• written, edited, excerpted, or published specifically for, or at the request of, a drug or device manufacturer;
or
• edited or significantly influenced by a drug or device manufacturer or any individuals having a financial
relationship with the manufacturer.
The information contained in the above scientific or medical journal article or reference publications should
address adequate and well-controlled clinical Investigations that are considered scientifically sound by experts
with scientific training and experience to evaluate the safety or effectiveness of the drug or device-. The
information must not:
• be false or misleading, such as a journal article or reference text that Is Inconsistent with the weight of
credible evidence derived from adequate and well-controlled clinical investigations (e.g., where a significant
number of other studies contradict the article or reference text's conclusions), that has been withdrawn by
the journal or disclaimed by the author, or that discusses a clinical investigation where FDA has previously
informed the company that the clinical investigation is not adequate and well-controlled; or
• pose a significant risk to the public health.
The following publications are examples of publications that would not be considered consistent with the Good
Reprint Practices outlined in this draft guidance:
•
•
•
•

letters to the editor;
abstracts of a publication;
reports of Phase 1 trials in healthy subjects; or
reference publications that contain little or no substantive discussion of the relevant investigation or data.
B.

Manner in which to Disseminate Scientific•»and Medical Information

Scientific or medical Information that is distributed should:
•
•
•
•

be in the form of an unabridged reprint, copy of an article, or reference publication;
not be marked, highlighted, summarized, or characterized by the manufacturer in any way;
be accompanied by the approved labeling for the drug or medical device;
be accompanied by a comprehensive bibliography of publications discussing adequate and well-controlled
clinical studies published in a medical journal or medical or scientific text that have been previously
published about the use of the drug or medical device covered by the Information disseminated (unless the
information already includes such a bibliography);
• In cases where the conclusions of article or text to be disseminated have been specifically called into
question by another article(s) or text(s), be disseminated with a representative publication that reaches
contrary or different conclusions regarding the unapproved use; and

• be distributed separately from information that is promotional in nature. For example, if a sales
representative delivers a reprint to a physician in his office, the reprint should not be physically attached to
any promotional material the sales representative uses or delivers during the office visit and should not be
the subject of discussion between the sales representative and the physician during the sales visit.3
Similarly, while reprints may be distributed at medical or scientific conferences in settings appropriate for
scientific exchange, reprints should not be distributed in promotional exhibit halls or during promotional
speakers’ programs.
The journal reprint or reference publication should be accompanied by a prominently displayed and
permanently affixed statement disclosing:
• that the uses described in the information have not been approved or cleared by FDA, as applicable to the
described drug or medical device;
• the manufacturer's interest in the drug or medical device that is the subject of the journal reprint or
reference text;
• any author known to the manufacturer as having a financial interest in the product or manufacturer or
receiving compensation from the manufacturer, if applicable;
• any person known to the manufacturer who has provided funding for the study, if applicable; and
• any significant risks or safety concerns known to the manufacturer concerning the unapproved use that are
not discussed in the journal article or reference text.

V.

Summary

FDA recognizes that the public health can be served when health care professionals receive truthful and nonmisleading scientific and medical information on unapproved uses of approved or cleared medical products.
Accordingly, If a manufacturer follows the recommendations described in Section IV of this draft guidance and
there is no unlawful promotion of the product, FDA does not intend to use the distribution of such medical and
scientific information as evidence of an intent by the manufacturer that the product be used for an unapproved
use.6

Footnotes
- As used in this draft guidance, the term "drug1' includes biological products licensed under Section 351(a) of
the Public Health Service Act. See 42 U.S.C. § 262(j).
2 As used in this draft guidance, the term '‘manufacturer” means a person who manufactures a drug or device
or who is licensed by such person to distribute or market the drug or device. The term may also include the
sponsor of the approved, licensed, or cleared drug or device.
3- This draft guidance does not apply to scientific or medical Information distributed in response to unsolicited
requests for scientific or medical information from health care professionals. See 59 Fed. Reg. 59820, 59823
(Novernber 18, 1994).
- In the case of medical devices, journal articles or reference publications discussing significant non-clinical
research may be consistent with this draft guidance.
- To the extent that the recipients of such information have questions, the Agency recommends that the sales
representative refer such questions to a medical/scientific officer or department, and that the officer or
department to which the referral is made be separate from the sales and/or marketing departments.
- Given the sunset of FDAMA § 401, the other elements that comprised § 401 which are not specifically
described in this draft guidance are no longer applicable.
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COMPLAINT FOR INJUNCTIVE AND OTHER RELIEF
1.

Attorney General G. STEVEN ROWE, on behalf o f the MAINE, brings this

civil action in the public interest against DEFENDANT PFIZER INC for violating The
Maine Unfair Trade Practices Act 5 M.R.S.A. §207 (MUTPA) as follows:

PARTIES
2.

Plaintiff, the MAINE, represented by Attorney General G. Steven Rowe, who

brings this action in the public interest pursuant to the authority granted under 5
M.R.S.A.§209.
3.

Defendant Pfizer Inc, (“Pfizer”) is a Delaware corporation with its principal

place o f business in New York. At all relevant times, Pfizer did business in the State of
Maine selling and promoting prescription drugs, including Bextra® and Celebrex®. In
2002, Pfizer purchased Pharmacia, a Delaware corporation, and merged the two
companies’ Bextra® and Celebrex® sales forces. Prior to this sale, the two companies’
co-marketed Bextra® and Celebrex® and closely coordinated all promotional efforts. In
addition for its own conduct marketing Bextra® and Celebrex®, Defendant Pfizer is also

responsible for Pharmacia’s conduct. The conduct of both Pfizer and Pharmacia shall
hereinafter be referred to collectively as conduct by DEFENDANT.
4.

DEFENDANT at all relevant times has transacted business in the State o f

Maine. The violations o f law alleged herein have been and are being carried out within
Maine.

JURISDICTION AND VENUE
5.

This Court has jurisdiction over the subject matter o f this action pursuant to 5

M.R.S.A.§209 and 4 M.R.S.A. §105 Venue in this court is proper under 5
M.R.S.A.§209.

SUMMARY OF THE ACTION
6.

Attorney General Rowe brings this Complaint because DEFENDANT

engaged in repeated unfair and deceptive acts, methods and practices with the purpose o f
achieving greater sales o f Bextra® than it otherwise would have been able to achieve had
it complied with the law. DEFENDANT achieved these sales in large part by misleading
physicians and health professionals, consumers and others about the safety and efficacy
o f Bextra®, and about the indications for which Bextra® was approved.
7.

DEFENDANT’S unlawful marketing o f Bextra® began in 2001 after the U.S.

Food and Drug Administration (“FDA”) declined to approve Bextra® for all o f the uses
and indications that DEFENDANT was counting on to make Bextra® a financial
“blockbuster.” Rather than simply marketing Bextra® for the more limited FDAapproved indications, DEFENDANT engaged in an aggressive, deceptive, and unlawful
“off label” marketing campaign to increase sales o f Bextra®, a COX-2 inhibitor, to treat
acute pain, perioperative pain and opioid sparing uses. These indications or uses for

2

Bextra® are referred to as “off-label” uses because they have not been approved by the
FDA. Bextra®'s FDA-approved “on-label” use is limited to 10 milligram doses for the
treatment o f pain associated with rheumatoid arthritis and osteo-arthritis and 20
milligram doses for pain associated with primary dysmenorrhea (menstrual pain).
8.

As a part o f it's “off-label” campaign, DEFENDANT misrepresented that

Bextra® was a safe alternative to schedule 2 narcotics and traditional nonsteroidal anti
inflammatories (“NSAIDs”) typically used in the treatment o f acute and perioperative
pain, marketed Bextra® as reducing serious gastrointestinal side effects without
possessing competent and reliable evidence to support this claim, and failed to disclose
that Bextra® increased the risk o f serious adverse events including death.
9.

DEFENDANT also commissioned and disseminated hundreds o f thousands o f

copies o f positive studies relating to off-label uses of Bextra® without also providing
negative studies; distributed hundreds o f thousands o f 20 milligram doses o f Bextra® to
medical professionals such as orthopedic surgeons who do not generally prescribe for
menstrual pain with the intent that the sample would be used off label; co-opted
influential doctors to encourage off-labeling prescribing; provided meals and gifts to
doctors who prescribed Bextra® off-label; promoted Continuing Medical Education
(“CME”) classes that encouraged off-label uses; rewarded high off-label prescribers with
paid “preceptorships” and consultancies; disseminated print advertisements with text and
imagery that communicated Bextra®'s supposed efficacy against acute pain; and
encouraged sales representatives to promote off-label uses in their sales calls. Instead of
marketing Bextra® safely and responsibly, DEFENDANT was driven by its desire to
maximize profits.

3

STATEMENT OF FACTS
Cox-2 Painkillers Were Developed in a Lucrative Market.
10.

NSAIDs such as naproxen. (Aleve®) and ibuprofen (Advil®) have been widely

prescribed for many years to treat the symptoms o f arthritis as well as chronic and acute
pain from other causes. NSAIDs are highly effective against pain and inflammation;
however, they can cause gastrointestinal (“GI”) side effects, including serious adverse
events such as obstructions, bleeds, and perforations.

These drugs are also sold

over-the-counter (“OTC”) at dosages lower than prescription strength. For the most part,
NSAIDs are available generically and are thus significantly cheaper than branded COX-2
drugs.
11.

NSAIDs work against pain and inflammation by inhibiting enzymes known as

cyclo-oxygenase or COX. There are two forms o f COX enzymes: COX-1 and COX-2.
COX-1 is involved in the maintenance and repair o f the GI system.
12.

Selective COX-2 inhibitors (“COX-2 drugs”) are drugs that block COX-2

without affecting COX-1. This class o f drugs was developed in the 1990s in hope of
reducing pain and inflammation without blocking COX-l's beneficial effect on the GI
system; however, the scientific studies o f COX-2 drugs have been inconclusive regarding
gastrointestinal safety.
13.

The scientific rationale and justification for COX-2 drugs was safety, not

efficacy. No scientifically valid clinical trial has ever found COX-2 drugs to be more
effective for treatment of pain and inflammation than traditional NSAIDs.
14.

There are significant concerns that COX-2 drugs as a class may increase the

risk o f cardiovascular (“CV") adverse events such as stroke and heart attacks..

4

15.

In total, three COX-2 drugs have been approved for sale in the United States:

Celebrex® (celecoxib), Vioxx® (rofecoxib), and Bextra® (valdecoxib). DEFENDANT
began marketing Celebrex® in early 1999 and Merck followed several months later with
Vioxx®. In early 2002, DEFENDANT began marketing Bextra®. Ultimately, Vioxx®
was withdrawn from the market in 2004; Bextra® was withdrawn in 2005, and that same
year, Celebrex® was given a "black box" warning on its label concerning CV risks
associated with COX-2 drugs.
16.

DEFENDANT competed vigorously with Merck for the rapidly expanding

COX-2 market. DEFENDANT’S sales representatives were paid significant bonuses to
get doctors to switch patients from Vioxx® to Celebrex® or Bextra®.
17.

Celebrex® was disadvantaged in its competition with Vioxx® because unlike

Vioxx®, Celebrex® was not initially approved for the treatment o f acute pain. Although
eventually Celebrex® was approved for this indication, the late approval impaired
Celebrex®'s ability to compete in the acute pain market and many doctors considered
Celebrex® less effective against acute pain.
D efendant Developed Bextra® to B e a “Blockbuster” Painkiller but Studies Revealed
Safety Concerns.
18.

DEFENDANT planned to "create the next [COX-2] blockbuster" by marketing

Bextra® as a "powerful agent" for both acute and chronic pain with strength equal to that
o f a schedule 2 narcotic. Bextra®'s initial product profile identified acute pain, opioid
sparing, and preemptive analgesia associated with the treatment o f surgical pain as
Bextra®'s distinguishing qualities. By focusing on these qualities, DEFENDANT sought
to supplement Celebrex®'s perceived weaknesses against acute pain with Bextra®'s
strength and prevent Bextra® from cannibalizing Celebrex® sales.
5

Bextra® would

primarily target young active patients with acute pain while Celebrex® would primarily
target older patients with chronic pain (e.g. - pain associated with arthritis). Bextra®
would compete directly against Vioxx®in the acute pain market while Celebrex® would
compete primarily against traditional NSAIDs including OTC drugs, for chronic pain.
19.

On November 27, 2001, the FDA approved the lOmg dose Bextra® for the

treatment o f pain associated with rheumatoid arthritis and osteo-arthritis and the 20
milligram dose for pain associated with primary dysmenorrhea, but expressly rejected
Bextra®’s use at any dose for acute and perioperative pain and opioid sparing indications.
The FDA rejected Bextra® for those uses primarily because the Coronary Artery Bypass
Graft Study 035 (“CABG I”) demonstrated an excess of serious adverse events including
death in association with Bextra® and Bextra®’s pro-drug, paracoxib.
20.

CABG I was a randomized, double-blind comparison o f two groups o f patients

who underwent coronary artery bypass graft surgery. One group in the study received
Bextra® and paracoxib, along with narcotics, to treat perioperative pain. The other group
only received narcotics (also known as the "standard of care"). DEFENDANT’S goal for
CABG I was to demonstrate that Bextra® was safe and effective to treat surgical pain and
reduce the incidence of narcotic related adverse events such as nausea, constipation, and
somnambulence. The results o f the CABG I study, however, showed that although
patients given Bextra® used fewer narcotics, there was no reduction in narcotic related
side effects. Further, patients given Bextra® suffered twice as many Serious Adverse
Events (“SAEs”) compared to patients who did not receive Bextra®.
21.

To minimize the safety concerns raised by CABG I, DEFENDANT compared

Bextra®'s SAE rate with observational reports outside the study and claimed that
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Bextra®'s SAE rate was within normal limits. This substitution of an after the fact control
group data is scientifically dishonest and contrary to generally accepted scientific
methods. DEFENDANT attempted to further minimize the negative results of CABG I
by claiming there was a “failure o f randomization" that caused weaker patients to be
placed in the Bextra® test group.
22.

In addition, in an attempt to frame the negative CABG I results as a fluke, on

or about January 28, 2003, DEFENDANT began a second clinical trial relating to
Bextra® and CABG surgery. The “CABG II” study compared three similarly sized
groups: patients who received narcotics; patients who received narcotics plus Bextra®;
and patients who received narcotics, Bextra®, and paracoxib.
23.

DEFENDANT enrolled patients into their CABG II study without disclosing to

them that their counterparts in CABG I experienced a doubling o f SAEs. Rather, the
increased SAE rate was minimized and potential subjects were told that side effects in
CABG I were within the expected number o f side effects typically seen in CABG
surgeries.
24.

CABG II confirmed the risk o f high dose Bextra® for post-operative pain relief:

patients who received Bextra® experienced significantly more heart attacks and other
cardiovascular problems compared to patients who did not receive Bextra®.
25.

CABG II combined with CABG I raised significant concerns about the safety

of Bextra® for all patients, even at low doses. Nonetheless, DEFENDANT continued to
promote high dose Bextra® for acute pain and peri-operative uses.
26.

In November 2004, the FDA required DEFENDANT to disclose the negative

SAE data results of both CABG studies in a revised package insert for Bextra®.
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27.

Nonetheless, beginning in 2001 after the FDA denial o f certain indications and

despite clear evidence of risks associated with high dosing of Bextra®, DEFENDANT
proceeded with its original marketing plan to market Bextra® for the now FDAdisapproved indications of acute, perioperative pain and opioid sparing indications.
D efendant Created and Distributed Biased Science and Unfair and Imbalanced
Inform ation.
28.

As part o f their illegal marketing efforts, DEFENDANT unlawfully distributed

and discussed many studies that described off-label indications. Notwithstanding official
and

legal

admonitions

against

using

off-label

studies

for marketing

efforts,

DEFENDANT disseminated hundreds o f thousands of clinical studies that supported
using Bextra® for acute and perioperative pain and opioid sparing use for the purpose of
promoting Bextra® for off-label use. Additionally, DEFENDANT did not comply with
requirements to balance favorable information by the equal distribution of relevant
unfavorable studies, and DEFENDANT did not disclose the negative results from the
CABG studies or the FDA's rejection o f Bextra® for acute, perioperative pain and opioid
sparing indications.
29.

DEFENDANT disseminated hundreds of thousands o f copies of an article

entitled “Valdecoxib, a COX-2 — Specific Inhibitor, Is an Efficacious Opioid-Sparing
Analgesic in Patients Undergoing Hip Arthroplasty,” by Frederic Camu, M.D. (“Camu”),
' which' was published in the American Journal o f Therapeutics in 2002. DEFENDANT
distributed the Camu study to orthopedic surgeons, anesthesiologists, and other surgical
specialists knowing these specialists would be prescribing Bextra® off-label for
perioperative pain and opioid sparing.
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30.

DEFENDANT distributed hundreds o f thousands of copies of an article

entitled “Valdecoxib Does Not Impair Platelet Function,” by Philip T. Leese, M.D.
(“Leese”), which was published in the Journal of Emergency Medicine in 2002.
DEFENDANT distributed the Leese article as proof that Bextra® could be used for
perioperative pain without causing increased bleeding after surgery.
31.

DEFENDANT also distributed hundreds of thousands of copies o f an article

entitled “The Analgesic Efficacy o f Valdecoxib Versus. Oxycodone/Acetaminophen after
Oral Surgery,” by Stephen E. Daniels, D.O. (“Daniels”), which was published in the
Journal o f the American Dental Association (JADA) in 2002.

DEFENDANT

commissioned the Daniels study as part o f a strategy to create and disseminate medical
studies that supported prescribing Bextra® for perioperative pain and opioid sparing use.
The Daniels study was not conducted by a mainstream academic organization; rather
DEFENDANT hired SCIREX, a contract research organization owned by a large
advertising company, and hired by DEFENDANT. The Daniels study was designed to
produce misleading study results because it compared Bextra® to a single dose o f a
medicine that is usually given in multiple doses. Although the Daniels study was
published by Journal o f the American Dental Association (“JADA”), one o f the journal’s
editors later explained that they were not told that Bextra® was disapproved for the
treatment o f acute pain. Had JADA’s editors known the truth, the Daniels study would
not have been published.
32.

DEFENDANT widely disseminated the Camu, Leese, and Daniels studies to its

sales representatives, urged them to distribute the articles on their sales calls, and
provided them with discussion notes that enabled sales representatives to discuss these
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off-label studies during their sales calls. Although the materials DEFENDANT produced
for sales representatives often contained a “do not detail” advisement cautioning against
any discussion o f the studies during sales calls, the warning was illusory and widely
ignored.
33.

DEFENDANT also attempted to hire influential medical professionals to

present the results o f these studies in order to give a false appearance of objection to
DEFENDANT’S self-generated and financed study results.
34.

In 2003, the Journal o f Thoracic and Cardiac Surgery published CABG I as an

article entitled “Efficacy and Safety o f the Cyclooxygenase 2 Inhibitors Parecoxib and
Yaldecoxib in Patients Undergoing Coronary Artery Bypass Surgery” by Elisabeth Ott,
M.D. (“Ott”). This article raised important concerns about the safety of high dose
Bextra® for treatment o f acute and perioperative pain and for opioid sparing uses and
suggested the need for a comprehensive evaluation of a large-scale trial before using
Bextra® to treat vulnerable patients. DEFENDANT promoted Bextra® for acute and
perioperative pain and opioid sparing uses yet failed to disclose this article to the medical
community and did not approve it for distribution by sales representatives.
35.

DEFENDANT also promoted off-label uses o f Bextra® in medical inquiry

response letters.

FDA regulations permit drug manufacturers to provide off-label

information in response to an unsolicited inquiry from a medical professional so long as
•
•
«.
the responsive material contains balanced information and is not promotional. Similar to
its strategy o f distributing only favorable off-label medical articles, DEFENDANT
disclosed only favorable data about acute and perioperative pain and opioid sparing
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indications in their responses to medical inquiries and omitted negative CABG I results
and the FDA denials.
D efendant Improperly Distributed Free Sam ples o f Bextra® with the In ten t to Have
Samples Used fo r Off-label Indications.
36.

DEFENDANT promoted off-label use of Bextra® to treat acute and

perioperative pain and opioid sparing by giving hundreds o f thousands o f 20 milligram
Bextra® samples to surgeons, anesthesiologists, and other surgical and pain specialists
who do not customarily treat severe menstrual cramps, but who do treat acute and peri
operative pain. DEFENDANT intended for medical specialists to use the 20 milligram
samples to treat acute and perioperative pain and for opioid sparing use but failed to
disclose the negative results from the CABG I and CABG II studies and failed to disclose
that FDA had rejected these indications due to concerns about their safety.
D efendant Em ployed an Enorm ous Sales S ta ff to M arket Bextra® fo r O ff-Label Uses.
37.

DEFENDANT relied heavily on its sales staff to market Bextra® for off-label

and FDA-denied indications. DEFENDANT produced deceptive sales messages that
promoted Bextra® for acute and perioperative pain and opioid sparing and trained sales
representatives to effectively use this messaging to increase off-label sales. Sales
representatives promoted Bextra®’s off-label indications to health care providers and were
encouraged to detail health care providers extensively about these FDA-denied
indications.
38.

Sales managers carefully tracked sales representatives' success in conveying

DEFENDANT’S messages by monitoring electronic call notes submitted by sales
representatives and accompanying them on sales calls. DEFENDANT also knew that
sales representatives were detailing Bextra® for acute and perioperative pain based on
11

surveys conducted by consultants hired by DEFENDANT to track and monitor
prescribing information.
39.

DEFENDANT sought to increase Bextra® sales for acute and perioperative

pain and opioid sparing by aggressively targeting surgeons, surgery centers, and hospitals
to get Bextra® placed on “standing orders” and “protocols” for these indications. Surgery
centers and hospitals rely on standing orders and protocols for analgesic dosing regimes
associated with perioperative pain.

DEFENDANT’S success in placing Bextra® on

surgical standing orders directly increased Bextra® sales, served as a powerful tool for
promoting Bextra® to other doctors and hospitals, and increased the likelihood that
surgical patients would remain on Bextra® to treat chronic pain conditions after surgery.
40.

DEFENDANT also obtained examples of surgical protocols and standing

orders that included analgesic dosing regimes for Bextra® and disseminated these
samples to sales representatives.

DEFENDANT held contests and rewarded sales

representatives with recognition, accolades, and cash equivalent prizes for obtaining high
volume standing order sales.
D efendant Engaged in O ff-Label Advertising to Consumers and Providers Using the
Pretense o f Education.
41.

Physician education programs were another integral part o f DEFENDANT’S

scheme to promote Bextra® for acute and perioperative pain and opioid sparing
indications. DEFENDANT hired surgeons, anesthesiologists, and other pain specialists
to conduct physician education programs ranging from informal luncheon presentations
to Continuing Medical Education programs. DEFENDANT knew off-label topics would
be discussed at these programs and provided speakers with presentation slides containing
favorable off-label data and information about Bextra®.
12

42.

DEFENDANT’S market research indicated that more patients suffered from

non-arthritis pain than arthritis pain.

To reach beyond the arthritis pain market,

DEFENDANT developed and widely used marketing materials that promoted Bextra® to
treat acute pain caused by sprains, strains, tendonitis, and bursitis.

To avoid the

appearance o f off-label marketing, however, DEFENDANT’S sales messages used
euphemisms for acute pain such as "tough pain," "flare pain," "acute pain condition," and
"episodic pain" and visual imagery that evoked strong and powerful pain relief.
43.

DEFENDANT also used patient-type marketing to enhance its acute pain

message for Bextra®. Throughout its marketing campaign, DEFENDANT consistently
targeted the young active “weekend warrior” patient with tough episodic pain for
Bextra®. In contrast, and to distinguish the target market for Celebrex®, DEFENDANT
promoted Celebrex® for the older patient suffering from chronic pain.
44.

DEFENDANT’S marketing surveys, focus groups, and feedback from its field

sales force confirmed that doctors consistently perceived Bextra®'s strong powerful pain
relief messaging as targeting the acute pain market.
45.

DEFENDANT also promoted its “weekend warrior” imagery in its direct-to-

consumer advertising. DEFENDANT distributed hundreds o f thousands o f copies of a
self-published periodical called Perform Magazine that contained multiple images and
messages promoting Bextra®'s strong powerful pain relief. Perform Magazine was sent
to subscribers o f People magazine and widely distributed in patient waiting rooms.
46.

DEFENDANT invited surgeons and other pain specialists who were likely to

prescribe Bextra® off-label to so-called “consultant” meetings. Although DEFENDANT
claimed these meetings were not promotional, they conducted return on investment
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analysis on some attendees to determine whether there was a sufficient increase in
prescriptions to financially justify the costs o f the meetings.
D efendant Gave Im proper Inducem ents, Payments, and Gifts to Physicians.
47.

To illegally promote Bextra® off-label from within the medical community,

DEFENDANT also hired surgeons, podiatrists, anesthesiologists, and other specialties to
conduct Bextra® off-label dinner talks and round tables. DEFENDANT sought out and
developed physician speakers who were high prescribers o f Bextra® and supported its
off-label use — these health care providers were then paid to give lunch or dinner talks
relating to off-label use o f Bextra®.
48.

DEFENDANT maintained a stable o f recommended and paid physician-

speakers that sales staff could use for off-label Bextra® dinner talks. Sales staff often
worked with physicians on their presentations, and encouraged health care providers to
talk about off-label uses, even though this practice is prohibited. Talks were conducted at
expensive restaurants. DEFENDANT conducted analyses on physicians to confirm that
their prescribing behavior increased after speaking or after attending dinner programs.
49.

DEFENDANT rewarded doctors who were high off-label prescribers o f

Bextra® with "preceptorships" in which the doctor was paid up to $500 to allow Bextra®
sales representatives to follow him or her around on clinical rounds and attend surgeries.
50.

DEFENDANT used preceptorships to gain access to doctors who otherwise

would not allow sales representatives to visit their office. During the preceptorship, the
sales representatives were encouraged to discuss using Bextra® to treat acute and
perioperative pain.
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51.

DEFENDANT also cultivated off-label Bextra® prescribes by rewarding

certain prescribers with clinical research grants and contracts.
52.

In addition to gifts to prescribers, DEFENDANT provided grants to certain

medical centers and hospitals and leveraged the resultant “goodwill” to promote off-label
use o f Bextra®.
To E nhance Its U nlawful M arketing Campaign, D efendant Concealed and
M isrepresented Bextra" ’s Safety and Risks.
53.

As DEFENDANT marketed Bextra® to more health care providers, for more

patients, and for a wider assortment o f illnesses and pain types, DEFENDANT
consistently avoided, minimized, and failed to disclose material health and safety risks.
DEFENDANT deceptively marketed Bextra® as the most powerful non-narcotic
medication without clinically reliable evidence for such a claim, and while omitting
important information that showed Bextra® was no better and potentially more dangerous
than traditional NSAIDs in treating pain.
54.

DEFENDANT’S decision to minimize or fail to disclose the results from

CABG I, the study which was the basis for the FDA’s denial o f Bextra® for acute pain
prevented doctors from fully educating themselves about Bextra® and created a
dangerous situation where health care providers were prescribing a drug without knowing
all of the risks.
55.

DEFENDANT also deceptively promoted Bextra®’s*-gastrointestinal safety in

brochures mailed directly to consumers.

Although Bextra®’s FDA approval label

cautioned that Bextra® could cause serious and life-threatening gastrointestinal side
effects, including bleeding in the stomach and intestines, DEFENDANT’S direct to
consumer brochures misrepresented that, for patients who take Bextra®, the “stomach
15

stays protected.” DEFENDANT ran a similarly deceptive advertisement in Perform
Magazine.
56.

DEFENDANT’S sales staff told health care providers that Bextra® was safe

and effective, without affirmatively explaining side effects or adverse events.
DEFENDANT’S sales executives specifically told sales staff not to initiate discussion o f
Bextra® safety.
57.

DEFENDANT also attempted to confuse health care providers to believe

positive Celebrex® data also applied to Bextra®. DEFENDANT promoted both Bextra®
and Celebrex® at the same time and their marketing materials and representations
intentionally conflated research data so that Celebrex® studies were used to explain the
safety and efficacy o f Bextra®, even though Celebrex® was a different drug and approved
for different indications.
D E F E N D A N T ’S U nlaw ful M arketing Scheme H ad a Pow erful Effect.
58.

DEFENDANT’S promotional scheme for Bextra® was highly successful. Total

Bextra® sales approached four billion dollars, most o f which were for acute and
perioperative pain and opioid sparing indications and not for the 10 milligram dose
treatment o f pain associated with rheumatoid arthritis and osteo-arthritis and the 20
milligram dose treatment for pain associated with primary dysmenorrhea.

CAUSE OF ACTION AGAINST DEFENDANT FOR
UNFAIR, UNCONSCIONABLE, OR DECEPTIVE ACTS OR PRACTICES
MUPA 5 M.R.S.A. § 207
59.

Paragraphs 1-58 o f this complaint are incorporated herein as though set forth in

full. 5 M.R.S.A.§209 authorizes the Attorney General to bring an action to enjoin a
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defendant from engaging in a method, act, or practice that is in violation of 5
M.R.S.A.§207.
60.

By engaging in the acts and practices described above, DEFENDANT has

engaged unfair or deceptive acts and practices in violation of 5 M .R.SA .§207 by
misrepresenting the characteristics, uses, benefits, and qualities of Bextra®. Namely,
DEFENDANT violated 5 M .R.S.A.§207 by:
a) promoting Bextra® off-label for acute pain, post surgery analgesia and
opioid sparing without disclosing that the FDA rejected DEFENDANT
application to promote for these indications;
b) promoting Bextra® 20mg off-label as safe and effective for conditions other
than primary dysmenorrhea;
c) misrepresenting the safety and efficacy o f Bextra for treatment o f acute
pain, post surgery analgesia, and opioid sparing use;
d) misrepresenting the gastrointestinal safety o f Bextra®; and
e) conflating information to mislead doctors to believe that positive
information about one drug also applied to the other.

61.

DEFENDANT engaged in acts and practices described above when it knew,

or should have known, that its conduct was unfair or deceptive in violation o f 5
M.R.S.A.§207.

PRAYER FOR RELIEF
WHEREFORE, PLAINTIFF respectfully requests that this Court:
1. Adjudge and decree that DEFENDANT engaged in acts or practices in violation of 5
M.R.S.A.§207, as previously set forth.
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2. Permanently enjoin and restrain the DEFENDANT from engaging in deceptive and
unfair practices set forth herein and from violating 5 M.R.S.A.§207.
3. Adjudge and decree that the DEFENDANT are liable to the State for the reasonable
costs and expenses o f the investigation and prosecution o f the DEFENDANT’S
actions, including attorneys’ fees.
4. Assess, and impose upon DEFENDANT a civil penalty pursuant to 5 M.R.S.A.§20 o f
(UP TO $10,000) for each unfair or deceptive act or practice alleged herein.
5. Grant Plaintiff such other and further relief as this Court deems just, equitable
and appropriate.
Dated: October 22, 2008

G. STEVEN ROWE
ATTORNEY GENERAL

LINDA CONTI ME BAR NO 3638
ASSISTANT ATTORNEYS GENERAL
STATE HOUSE STATION 6
AUGUSTA, ME 04333
(207) 626-8591
Linda.Conti@Maine.gov
ATTORNEYS FOR STATE OF MAINE

18

?

STATE OF MAINE
SUPERIOR COURT
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Location__________
Docket N o .________
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Docket No. _________

STATE OF MAINE
Plaintiff
APPLICATION FOR TRANSFER TO
BUSINESS AND CONSUMER DOCKET

V.

PFIZER

INC
Defendant

I/We submit this application for transfer of the above-captioned case to the BCD, based on the following information:
NAME OF EACH PARTY SUBMITTING THIS APPLICATION;

1. Is at least one party a business entity?

[ 3 Yes

□

Plaintiff

Defen

J8T

□

□

□

□

□

□

□

No

2. List all plaintiffs and their counsel:
P L A IN T IF F S )

State of Maine

C O U N S E L (N A M E A N D A D D R E S S )

Linda J„ Conti,
Assistant: Attorney General
State House Station 6
Augusta ME 04333

3. List all defendants and their counsel:
D EFEN D A N TS)

PFIZER INC

C O U N S E L (N A M E A N D A D D R E S S )

Russell B. Pierce, Jr., Esq.
Norman Hanson
DeTroy, LLC
415 Congress St,,
P'.O. Box 4600
Portland ME 04112

a.

4. List any other cases with which this case is or may need be consolidated or coordinated:
C A S E C A P T IO N

BCD-001, Rev. 11/07

DOCKET NUM BER

C U R R E N T C O U R T L O C A T IO N

f

5. What is the subject matter of the primary cause of action in this case:
□

Breach o f Warranty
] Class Action
[~1 80C Appeal involving a business entity
CD Securities transactions
] Confidential or trade secret
f l Financial transactions
J S t Unfair trade practices
I I Commercial real estate

Breach of Contract
I I Breach of Fiduciary Duty
I I 80B Appeal involving a business entity
I I Internal governance o f a business entity
Shareholder derivative action
I~1 Intellectual property
I I U.C.C. transactions
Antitrust or other trade regulations
I I Other {describe): ____________________

NOT YET
DETERMINED

6. What is the status of this case:
NO

YES
a. Has service o f the com plaint been completed on all
p arties?.............................................................................
b. Are the pleadings closed? ...........................................
c. Is discovery co m p leted ?................................................
d. Is class action status so u g h t? ...........................................

e.
f.
g
h.
i.
j.
k.
l.

Scheduled for trial? I f so, w h e n ? ................................
Pretrial h e ld ? ...................................................................
Case management conference held? .........................
Jury trial? ......................................................................
Bench tr ia l? ......................................................................
ADR been attem p ted ?....................................................
Is file sealed (partial / e n tire )? ......................................
Will post-judgment judicial supervision be needed? .

□
□
□
□
□
□
□
□
□
□
□
□

□
□

□
□
□
□
□
□
□
□
□
□
□
□

□

□
□
□
□
□

□
□
□

□
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7. What is the estimated length of trial (in days)? _________

8. Identify nature and number of any pending pretrial motions:

9. Identify any novel and/or complex legal issues in this case:

10. Do all of the parties appearing in the case agree to a transfer?

YES

O

NO

CERTIFICATION OF SERVICE BY ATTORNEY OR PARTY SUBMITTING APPLICATION
I hereby certify that a copy was mailed/dettvered to all MtChsel and pro se parties of record on this date
SIGNED:

DATE
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ORDER (For BCD Court Use Only)

The above Application having been considered, it is ORDERED as follows:
I I The case'is ACCEPTED for transfer. The case file shall be transferred forthwith from the court in which the case is now
pending to the BCD.
I I The case is NOT ACCEPTED for transfer.
SIGNED (BCD Justice/Judge)

DATE

PLEASE NOTE THE FOLLOWING:
A. Failure to supply complete and accurate information may disqualify a case for consideration for transfer to
the BCD.
B. Information that does not fit on this form should be attached to a separate sheet and numbered to correspond
to the inquiries on the form.
C. This application should be filed with the court in which the case is currently pending.
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STATE OF MAINE
KENNEBEC, SS

STATE OF MAINE
PLAINTIFF

SUPERIOR COURT
Civil ACTION
Docket No. CV-08-

)
)
)
)

)

V.

PFIZER INC
DEFENDANT

CONSENT JUDGMENT

)
)
)
)

1.

The parties voluntarily enter into this Consent Judgment on the terms and
conditions set forth below.
Definitions:
a.

“Covered Conduct” shall mean Pfizer’s promotional and marketing

practices regarding the prescription drugs Celebrex® and Bextra®, that were the subject
o f an investigation by the Signatory Attorneys General under the State Consumer
Protection Laws.
b.

“Effective Date” shall mean the date by which Pfizer and ninety percent

(90%) of the States that comprise the Multistate Working Group have executed the
Consent Judgment.
c.

“FDA Amendments Act of 2007” (or “FDA Amendments Act” or “the

Act”) shall mean Public Law No. 110-85, which among other things, creates a federal
clinical trial registry and results data bank.
d.

“FDA’s Guidance for Industry” shall mean documents published by the

United States Department o f Health and Human Services, Food and Drug Administration
(FDA), that represent the FDA’s current recommendations on a topic.
CONSUMER PROTECTION! DIVISIOI
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l.

“Product” shall mean any prescription drug or biological product

manufactured, distributed, sold, marketed or promoted in the United States in any way.
m.

“Signatory Attomey(s) General” shall mean the Attorney General, or his

or her designee, o f each state in the Multistate Working Group.
n.

“State Consumer Protection Laws” shall mean the consumer protection

laws under which the Signatory Attorneys General have conducted their investigation.1

1 The States’ consumer protection statutes are: ALASKA - Unfair Trade Practices and
Consumer Protection Act, AS 45.50.471 et seq.; ARIZONA - Consumer Fraud Act,
A.R.S. § 44-1521 et seq:, ARKANSAS - Ark. Code Ann. § 4-88-101 et seq:,
CALIFORNIA - Bus. & Prof. Code §§ 17200 et seq. and 17500 et seq:, CONNECTICUT
- Conn. Gen. Stat. §§ 42-110a et seq:, DISTRICT OF COLUMBIA - Consumer
Protection Procedures Act, D.C. Code § 28-3901 et seq:, FLORIDA - Deceptive and
Unfair Trade Practices Act, Fla. Stat. Ch. 501.201 et seq:, IDAHO - Consumer
Protection Act, Idaho Code Section § 48-601 et seq:, ILLINOIS - Consumer Fraud and
Deceptive Business Practices Act, 815 ILCS § 505/1 et seq. (2006 State Bar Edition);
IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16; KANSAS - Consumer
Protection Act, K.S.A. 50-623 et seq:, KENTUCKY - Consumer Protection Statute, KRS
367.110 et seq:, MAINE - Unfair Trade Practices Act, 5 M.R.S.A. § 207 et seq:,
MARYLAND - Consumer Protection Act, Md. Code Ann., Com. Law § 13-101 et seq:,
MASSACHUSETTS - Consumer Protection Act, M.G.L. c. 93A et seq:, MICHIGAN Michigan Consumer Protection Act, MCL 445.901 et seq:, MONTANA - Mont. Code
Ann. § 30-14-101 et seq:, NEBRASKA - Uniform Deceptive Trade Practices Act, NRS
§ 87-301 et seq:, NEW JERSEY - New Jersey Consumer Fraud Act, 56:8-1 et seq:, NEW
YORK - General Business Law Article 22-A Sections 349, 350 and Executive Law
Section 63 (12); NEW MEXICO - Unfair Practices Act, NMSA 1978, § 57-12-1 et seq:,
NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq:,
NORTH CAROLINA - Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. § 751.1 etseq.; NORTH DAKOTA - Unlawful Sales or Advertising Practices, N.D. Cent.
Code. § 51-15-02 et seq:, OHIO - Consumer Sales Practices Act, R.C. 1345.01 et seq:,
OREGON - Unlawful Trade Practices Act, ORS 646.605 to 646.656; PENNSYLVANIA
- Unfair Trade Practices and Consumer Protection Law, 73 P.S. § 201-1 et seq:, SOUTH
CAROLINA - Unfair Trade Practices Act, S.C. CODE. ANN. Sections 39-5-10 et seq:,
SOUTH DAKOTA - Deceptive Trade Practices Act, S.D. Codified Laws § 37-24 et seq:,
TENNESSEE - Consumer Protection Act, Tenn. Code Ann. §§ 47-18-101 et seq:,
TEXAS - Deceptive Trade Practices - Consumer Protection Act, Tex. Bus. and Com.
Code § 17.47 et seq:, VERMONT - Consumer Fraud Act, 9 V.S.A. § 2451 et seq:,
W ASHINGTON - Unfair Business Practices/Consumer Protection Act, R.C.W. 19.86 et
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(c)

It is the intent o f the Parties that this Judgment not be admissible in other

cases or binding on Pfizer in any respect other than in connection with the enforcement o f
this Judgment.
(d)

No part o f this Judgment shall create a private cause o f action or confer

any right to any third party for violation o f any federal or state statute except that a State
may file an action to enforce the terms of this Judgment.
(e)

All obligations undertaken by Pfizer in this Judgment shall apply

prospectively, except to the extent permitted by the National Library o f Medicine, Pfizer
shall submit, as soon as practicable, clinical trial results to the clinical trial registry and
results data bank created by the FDA Amendments Act for all “applicable clinical trials”
(as that term is defined by the Act) o f FDA-approved Pfizer Products that were initiated
after July 1, 2005.
3.
Pfizer shall register clinical trials and submit results to the registry and results
data bank as required by the FDA Amendments Act and any accompanying regulations
that may be promulgated pursuant to that Act.
4.
Pfizer shall not make any written or oral claim that is false, misleading or
deceptive regarding any FDA-approved Pfizer Product.
5.
Pfizer shall not make any written or oral promotional claims o f safety or
effectiveness for any FDA-approved Pfizer Product in a manner that violates the Food,
Drug and Cosmetic Act, 21 U.S.C. § 301 et seq. (“FDCA”), accompanying regulations,
or voluntary agreements with FDA, as interpreted by the FDA in a writing by the
Director o f the Center for Drug Evaluation at the FDA.
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Pfizer agrees to submit all new DTC television advertising campaigns for any
Pfizer Product to FDA for pre-review, to wait a reasonable time (not less than 45 days)
until Pfizer receives a response from FDA prior to running the advertising campaign,
and to modify such advertising consistent with any written comments from FDA,
whenever received. Simultaneous with running any new DTC television advertisement
for which FDA has not provided Pfizer with a pre-review response addressing the
substance o f the advertisement within the 45-day waiting period prescribed herein,
Pfizer shall provide written notice to the Multistate Executive Committee that Pfizer is
running the advertisement and that the FDA has not provided Pfizer with a pre-review
response addressing the substance o f the advertising within the 45-day waiting period,
and also provide a copy o f all material submitted to FDA for the review o f the subject
advertisement.
9.
Pfizer’s obligations with respect to Paragraph 7 shall remain in effect for eight
years following the Effective Date. Pfizer’s obligations with respect to Paragraph 8 shall
remain in effect for seven years following the Effective Date. W ith respect to
Paragraph 7, Pfizer shall abide by any such written recommendation so long as the
submission of the TV advertising campaign is made within eight years following the
Effective Date. With respect to Paragraph 8, Pfizer shall abide by any such written
recommendation so long as the submission o f the TV advertising campaign is made
within seven years o f the Effective Date.

10.
When presenting information in detailing pieces, brochures, booklets, mailing
pieces, published journals, magazines, other periodicals and newspapers, and broadcast
through media such as radio, television, the Internet, and telephone communications
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approved Pfizer Product’s safety, Pfizer shall not: (a) present favorable information or
conclusions from a study that is inadequate in design, scope, or conduct to furnish
significant support for such information or conclusions; (b) use the concept o f statistical
significance to support a claim that has not been demonstrated to have clinical
significance or validity, or fails to reveal the range o f variations around the quoted
average results; or (c) use statistical analyses and techniques on a retrospective basis to
discover and cite findings not soundly supported by the study, or to suggest scientific
validity and rigor for data from studies the design or protocol o f which are not amenable
to formal statistical evaluation.
13.
(a)

Pfizer shall comply with the ACCME Standards for Commercial

Support (a copy o f the current version is attached hereto as Appendix 1).
(b)

Any person who acts in a promotional capacity for Pfizer with respect to

an FDA approved Pfizer Product shall be obligated under his or her contract with Pfizer,
as a condition for any future promotional relationship with Pfizer, to disclose to
Continuing Medical Education (“CME”) participants orally and to the CME provider for
inclusion in the written materials the existence, nature and purpose of his or her
arrangement with Pfizer when a member of the faculty at a CME program if: (i) the
Product the faculty member promoted for Pfizer is in the same therapeutic category as
the subject o f the CME program, and (ii) the CME program occurs within 12 months of
the faculty member performing work for or receiving compensation from Pfizer. Such
disclosure shall set forth the type o f promotional work engaged in by the faculty member
and the name o f the therapeutic category with respect to such promotion.
(c)

Pfizer shall not provide funding for CME when Pfizer has knowledge at

the time the decision to fund the CME is made that a speaker at the CME has also been a
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17.
Pfizer shall not market two or more Products in a manner that falsely or misleadingly
conflates the various properties o f the respective Products.
18.
Pfizer shall not compensate physicians for conducting individual, observational
teaching sessions in their offices or in the hospital (“mentorships”) in which sales
representatives who detail a Product participate.
19.
Pfizer shall instruct investigators of Pfizer sponsored clinical trials regarding a
Product to obtain a legally effective informed consent from all study subjects or from the
subject’s legally authorized representative. If Pfizer provides the investigator (or the
investigator’s Institutional Review Board) with a model informed consent, Pfizer shall
not fail to include (a) a statement that the study involves research, an explanation o f the
purposes of the research and the expected duration o f the subject’s participation, a
description of the procedures to be followed, and identification o f any procedures which
are experimental; (b) a description o f any reasonably foreseeable risks or discomforts to
the subject; and (c) for research involving more than minimal risk, an explanation as to
whether any compensation and an explanation as to whether any medical treatments are
available if injury occurs and, if so, what they consist of, or where further information
may be obtained.

- 11 -

r

23.
Pfizer shall not disseminate a Medical Information Letter, an unabridged reprint or
copy o f an article from a Peer Reviewed Journal or a Reference Publication, or written
information through a Regional Medical Research Specialist (“RMRS”) describing any
Off-Label use o f a Product in response to an unsolicited request by a prescriber or other
health care professional unless (a) the information is about a clinical investigation with
respect to the Product and experts qualified by scientific training or experience to
evaluate the safety or effectiveness o f the Product would consider the subject o f the
clinical investigation to be scientifically sound or the information is an unabridged reprint
or copy of an article from a Peer Reviewed Journal or a Reference Publication; (b) the
information is accompanied by a comprehensive bibliography o f publications discussing
adequate and well-controlled clinical studies published in a medical journal or medical or
scientific text that have been previously published about the use o f the Product covered
by the information (unless the information is a Peer Reviewed Journal or Reference
Publication which already includes such a bibliography); and (c) in cases in which
experts qualified by scientific training or experience to evaluate the safety or
effectiveness o f the Product would consider the conclusion o f the information to have
been specifically called into question by another article(s) or text(s) that experts qualified
by scientific training or experience to evaluate the safety or effectiveness o f the Product
would consider to be scientifically sound, the information must be disseminated with a
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modify, the Attorney General shall notify Pfizer in writing if the Attorney General agrees
to the requested modification. The Attorney General shall not unreasonably withhold
his/her consent to the modification. The parties agree it would be unreasonable to
withhold consent to the terms provided in the draft “Guidance For Industry: Good
Reprint Practices For The Distribution Of Medical Journal Articles And Medical Or
Scientific Reference Publications On Unapproved New Uses O f Approved Drugs And
Approved Or Cleared Medical Devices,” dated February 15, 2008, and attached hereto as
Appendix 2, in the event that all such terms are included in the final Guidance For
Industry. In the event that all such terms are not included in the final Guidance for
Industry, the parties agree to consider whether any such terms that are included in the
final Guidance for Industry should form the basis o f a modification o f Paragraphs 22
through 24 o f this Judgment.
26.
Pfizer shall not disseminate any Medical Information Letter describing any Off-Label
use o f a Product that makes any false or misleading representation regarding a Product.
27.
Pfizer shall not disseminate samples of a Product with the intent o f increasing
Off-label prescribing o f the Product.
28.
When submitting clinical trials relating to Off-label indications to journals for
publication, Pfizer shall disclose to the journal that the FDA has not approved the drug
for the indication that was the subject of the clinical trial.
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32.
By its execution o f this Judgment, State o f Maine releases Pfizer and all o f its past
and present subsidiaries, affiliates, predecessors and successors (collectively, the
“Released Parties”) lfom the following: all civil claims, causes o f action, damages,
restitution, fines, costs, and penalties on behalf o f the State o f Maine under the abovecited consumer protection statutes arising from the Covered Conduct that is the subject of
this Judgment.
33.
Notwithstanding any term o f this Judgment, specifically reserved and excluded
from the Release in Paragraph 32 as to any entity or person, including Released Parties,
are any and all of the following:
(a)

Any criminal liability that any person or entity, including Released Parties,

has or may have to the State o f Maine.
(b)

Any civil or administrative liability that any person or entity, including

Released Parties, has or may have to the State o f Maine not expressly covered by the
release in Paragraph 32 above, including but not limited to any and all o f the following
claims:
i)

State or federal antitrust violations;

ii)

Reporting practices, including “best price”, “average wholesale

price” or “wholesale acquisition cost;”
iii)

Medicaid violations, including federal Medicaid drug rebate statute

violations, Medicaid fraud or abuse, and/or kickback violations related to any
State’s Medicaid program; and,
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respond to the notification; provided, however, that a Signatory Attorney General may
take any action if the Signatory Attorney General concludes that, because o f the specific
practice, a threat to the health or safety of the public requires immediate action.
Upon receipt of written notice, Pfizer shall provide a good-faith written response
to the Attorney General notification, containing either a statement explaining why Pfizer
believes it is in compliance with the Judgment, or a detailed explanation o f how the
alleged violation occurred and a statement explaining how Pfizer intends to cure the
alleged breach. Nothing in this paragraph shall be interpreted to limit the state's Civil
Investigative Demand (“CID”) or subpoena authority, to the extent such authority exists
under applicable state law, and Pfizer reserves all o f its rights with respect to a CID or
subpoena issued pursuant to such authority.
36.
Upon giving Pfizer thirty (30) days to respond to the notification described above,
the Signatory Attorney General shall also be permitted reasonable access to inspect and
copy relevant, non-privileged, non-work product records and documents in the
possession, custody or control o f Pfizer that relate to Pfizer’s compliance with each
provision o f this Judgment as to which cause that is legally sufficient in the State has
been shown. If the Signatory Attorney General makes or requests copies o f any
documents during the course o f that inspection, the Signatory Attorney General will
provide a list o f those documents to Pfizer.
37.
The State may assert any claim that Pfizer has violated this Judgment in a separate
civil action solely to enforce compliance with this Judgment, or to seek any other relief
afforded by law, but only after providing Pfizer an opportunity to respond to the
notification described in Paragraph 35 above; provided, however, that a Signatory
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ACCME STA N D A R D S
FOR C O M M E R C IA L
S U P P O R T SM
Standards to Ensure the

Independence of CME
Activities

ACCME

I

3.12 The provider may not use commercial support
to pay for travel, lodging, honoraria, or
personal expenses for non-teacher or nonauthor participants of a CME activity.
The
provider may use commercial support to pay
for travel, lodging, honoraria, or personal
expenses for bona fide employees and
volunteers of the provider, jo in t sponsor or
educational partner.
Accountability

3.13 The provider must be able to produce
accurate documentation detailing the receipt
and expenditure of the commercial support.
S T A N D A R D 4 . A p p r o p ria te M a n a g e m e n t o f j
A s s o c ia t e d C o m m e rc ia l P ro m o tio n
)

4.1 Arrangements for commercial exhibits or
advertisements cannot influence planning or
interfere with the presentation, nor can they be
a condition of the provision of commercial
support for CME activities.
4.2 Product-promotion material or product-specific
advertisement of any type is prohibited in or
during CME activities.
The juxtaposition of
editorial and advertising material on the same
products or subjects must be avoided. Live
(staffed exhibits, presentations) or enduring
(printed
or
electronic
advertisements)
promotional activities must be kept separate
from CME.
•

For

print,

a d v e r tis e m e n ts and p ro m o tio n a l m a te r ia ls will

n o t b e in te r le a f e d w ith in t h e pages o f t h e C M E c o n te n t.
A d v e r tis e m e n ts and p ro m o tio n a l m a te r ia ls m a y f a c e th e
f i r s t o r la s t pages o f p r in te d C M E c o n te n t as long as
th e s e m a te r ia ls a r e n o t r e la t e d t o t h e C M E c o n te n t th e y
fa c e

and a r e

n o t paid f o r by t h e c o m m e rc ia l s u p p o r te r s o f

t h e C M E a c tiv ity ,
•

For

computer based,

a d v e r tis e m e n ts

an d

p ro m o tio n al

m a te r ia ls w ill n o t b e v is ib le on t h e s c re e n a t t h e same
tim e as t h e C M E c o n te n t and n o t in t e r le a f e d

For

audio and video recording,

a d v e r tis e m e n ts

and

p ro m o tio n a l m a te ria ls w ill n o t b e in clu d ed w ith in t h e CM E.
T h e r e w ill b e no 'co m m ercial b re a k s .'
•

For

live,

face-to-face

CME,

a

CME

a c tiv ity .
of

P ro v id e rs

C om m e rc ial

5.1 The content or format of a CME activity or its
related materials must promote improvements
or quality in healthcare and not a specific
proprietary business interest of a commercial
interest.
5.2 Presentations must give a balanced view of
therapeutic options. Use of generic names will
contribute to this impartiality.
If the CME
educational material or content includes trade
names, where available trade names from
several companies should be used, not ju s t
trade names from a single company.
S T A N D A R D 6 . D is c lo s u r e s R e le v a n t to
P o t e n tia l C o m m e r c ia l B ia s
Relevant financial relationships of those with control over
CME content

6.1 An individual must disclose to learners any
relevant financial relationship(s), to include the
following information:
•
•
•

The name of the individual ;
The name of the commercial interest(s);
The nature of the relationship the person
has with each commercial interest.

6.2 For an individual with no relevant financial
relationship(s) the learners must be informed
that no relevant financial relationship(s) exist.

and

in t h e e d u c a tio n a l space im m e d ia te ly b e f o r e , d u rin g , or

r e p r e s e n ta tiv e s

S T A N D A R D 5. C o n te n t a n d F o r m a t w it h o u t
C o m m e r c ia l B ia s

Commercial support for the CME activity.
a d v e r tis e m e n ts

p ro m o tio n a l m a te ria ls c a n n o t be d is p la y e d o r d is tr ib u te d

a fte r

4.5 A provider cannot use a commercial interest as
the agent providing a CME activity to learners,
e.g., distribution of self-study CME activities or
arranging for electronic access to CME
activities. 3€

b e tw e e n

c o m p u te r 'windows' o r s c re e n s o f t h e C M E c o n te n t
•

4.4 Print or electronic information distributed about
the non-CME elements of a CME activity that
are not directly related to the transfer of
education to the learner, such as schedules and
content descriptions, may include productpromotion
material
or
product-specific
advertisement.

In te r e s ts

cannot
to

allow

engage

in

sales o r p ro m o tio n al a c tiv itie s w h ile in t h e sp a c e o r place
o f t h e C M E a c tiv ity .

4.3 Educational materials that are part of a CME
activity, such as slides, abstracts and handouts,
cannot contain any advertising, trade name or
a product-group message.

6.3 The source of all support from commercial
interests must be disclosed to learners. When
commercial support is ’in-kind' the nature of
the support must be disclosed to learners.
6.4 'Disclosure' must never include the use of a
trade name or a product-group message.
Timing of disclosure

6.5 A provider must disclose the above information
to learners prior to the beginning of the
educational activity.
ACCME®
2004, 2006, 2007 AC CME STANDARDS FOR COMMERCIAL SUPPORT™
PAGE 3 OF 3
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Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles
and Medical or Scientific Reference Publications on Unapproved New Uses of Approved
Drugs and Approved or Cleared Medical Devices
This draft guidance document represents the Food and Drug Administration's current thinking on this topic. It
does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You
may use an alternative approach if the approach satisfies the requirements of the applicable statutes and
regulations. If you want to discuss an alternative approach, please contact the appropriate FDA staff.

\
IV.

Agency Recommendations for Good Reprint Practices

Scientific and medical information that concerns the safety or effectiveness of an approved drug or approved
or cleared medical device for a new use that is not included in the product's approved labeling or statement of
intended uses (including unapproved or new uses of approved drugs and approved or cleared devices) is
often published in journal articles or reference publications. These publications are often distributed by
manufacturers to healthcare professionals or healthcare entities. When a manufacturer disseminates such
medical and scientific information, FDA recommends that the following principles of “Good Reprint Practices"
be followed.

A.

Types of Reprints/Articles/Reference Publications

A scientific or medical journal article that is distributed should:
• be published by an organization that has an editorial board that uses experts who have demonstrated
expertise in the subject of the article under review by the organization and who are independent of the
organization to review and objectively select, reject, or provide comments about proposed articles, and that
has a publicly stated policy, to which the organization adheres, of full disclosure of any conflict of interest or
biases for all authors, contributors, or editors associated with the journal or organization:
• be peer-reviewed and published in accordance with the peer-review procedures of the organization; and
• not be in the form of a special supplement or publication that has been funded in whole or in part by one or
more of the manufacturers of the product that is the subject of the article.
A scientific or medical reference publication that is distributed should not be:
• primarily distributed by a drug or device manufacturer, but should be generally available in bookstores or
other independent distribution channels where medical textbooks are sold;
• written, edited, excerpted, or published specifically for, or at the request of, a drug or device manufacturer;
or
• edited or significantly influenced by a drug or device manufacturer or any individuals having a financial
relationship with the manufacturer.
The information contained in the above scientific or medical journal article or reference publications should
address adequate and well-controlled clinical investigations that are considered scientifically sound by experts
with scientific training and experience to evaluate the safety or effectiveness of the drug or device-. The
information must not:
• be false or misleading, such as a journal article or reference text that is inconsistent with the weight of
credible evidence derived from adequate and well-controlled clinical investigations (e.g., where a significant
number of other studies contradict the article or reference text's conclusions), that has been withdrawn by
the journal or disclaimed by the author, or that discusses a clinical investigation where FDA has previously
informed the company that the clinical investigation is not adequate and well-controlled; or
• pose a significant risk to the public health.
The following publications are examples of publications that would not be considered consistent with the Good
Reprint Practices outlined in this draft guidance:
•
•
•
•

letters to the editor;
abstracts of a publication;
reports of Phase 1 trials in healthy subjects; or
reference publications that contain little or no substantive discussion of the relevant Investigation or data.

B.

Manner in which to Disseminate Scientific and Medical Information

Scientific or medical information that is distributed should:
•
•
•
•

be in the form of an unabridged reprint, copy of an article, or reference publication;
not be marked, highlighted, summarized, or characterized by the manufacturer in any way;
be accompanied by the approved labeling for the drug or medical device;
be accompanied by a comprehensive bibliography of publications discussing adequate and well-controlled
clinical studies published in a medical journal or medical or scientific text that have been previously
published about the use of the drug or medical device covered by the information disseminated (unless the
information already includes such a bibliography);
• In cases where the conclusions of article or text to be disseminated have been specifically called into
question by another article(s) or text(s), be disseminated with a representative publication that reaches
contrary or different conclusions regarding the unapproved use; and

